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1.1 ALVEOLAR EPITHELIUM 
The lung consists of functional respiratory units called alveoli and are lined by two 
distinct and specialized epithelial cell types, namely, Alveolar Epithelial Type I cells 
(AEC I) and Alveolar Epithelial Type II (AEC II) cells. AEC I are squamous. Their thin 
and flat morphology enables them to cover almost 95% of the total surface area of the 
alveoli. This large surface area makes them an effective air-blood barrier through which 
the actual gaseous exchange takes place. They also play a role in maintaining fluid 
homeostasis in the lung (Dobbs et al., 1998; Borok et al., 2002; Johnson et al., 2002; 
Ridge et al., 2003). Recently, it has been discovered that AEC I protects lung epithelium 
from oxidative injury (Chen et al., 2006). Also, new studies have shown that AEC I 
contains molecular machinery that has the potential for diverse functions including lung 
remodeling, angiogenesis matrix deposition and host defense (Qiao et al., 2003; Dahlin et 
al., 2004). These cells are considered to be terminally differentiated. Their architecture 
also make them prone to any kind of acute lung injury during which they are damaged 
significantly when compared to the AEC II cells.  
AEC II are cuboidal cells and are limited to the corners of the alveoli. They cover about 
5% of the surface area of the alveoli even though their number is greater than AEC I. 
They secrete the lung surfactant which reduces the normal surface tension at the alveolar 
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surface. These cells also have a role in fluid homeostasis (Jin et al., 2006). Most 
importantly they are considered to be progenitors of AEC I (Warburton & Bellusci, 
2004). When the AEC II population is damaged in the alveoli during acute lung injury or 
insult, the AEC II lose their quiescence, proliferate and differentiate into AEC I, thus 
restoring the AEC I population and thereby the air-blood barrier (Adamson & Bowden, 
1971; Evans et al., 1973; Uhal, 1997; Fehrenbach, 2001; Narasaraju et al., 2006). This 
trans-differentiation process is of high importance in maintaining the normal functionality 
of alveolar epithelium. 
Molecular mechanisms that govern this trans-differentiation process largely remain 
unclear. Keratinocyte Growth Factor (KGF) has been implicated in preventing this trans-
differentiation process in vitro by signaling mediated through JNK pathway (Qiao et al., 
2008). It has been thought that commitment of AEC I and II lineages requires continuous 
regulatory inputs and the fate can be altered by differential signaling (Danto et al., 1995). 
Some studies have looked at the genes and proteins that are differentially expressed in 
AEC II and trans-differentiated AEC I (Campbell et al., 1999; Qiao et al., 2003). This 
transformation has also been shown to be increased by exposure to nitric oxide (Evans et 
al., 1975). IL-1β expression mediated by EGF/TGFα signaling pathways have been 
implicated in helping with the trans-differentiation process following lung injury (Geiser, 
2003). IGF-1 signaling and the expression of an AEC I specific protein, RT140 are also 
thought to have a role in modulating this process (Maitre et al., 1995; Clegg et al., 2005).  
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I.2. TRANSFORMING GROWTH FACTOR BETA (TGF ß) PATHWAY  
Transforming Growth Factor beta (TGF β) superfamily consists of structurally related 
cytokines and is known to have important biological functions. The members of this 
family include isoforms of TGF β, bone morphogenetic proteins, inhibins and activins 
(Massague, 2000; Moustakas et al., 2001; Ten Dijke et al., 2002; Li et al., 2006). They 
mediate biological processes like proliferation, differentiation, migration and  apoptosis 
in various cell types (Roberts & Sporn, 1993; Schuster & Krieglstein, 2002; Huang & 
Huang, 2005).  TGF β has five isoforms namely TGF β1 (Derynck et al., 1985), TGF β2 
(Miller et al., 1989), TGF β3 (Derynck et al., 1988; Miller et al., 1989), TGF β4 
(Jakowlew et al., 1988) and TGF β5 (Kondaiah et al., 1990). Only TGF β1, TGF β2 and 
TGF β3 have been cloned from mammalian sources so far (Fitzpatrick et al., 1990).  
TGF β1 can act both in autocrine and paracrine manner and initiates signaling by binding 
to specific type II receptors (TβRII) receptors on the cell surface. (Shi & Massague, 
2003). This, in turn, brings type I receptors (TβRI)  closer to TβRII forming a hetero-
tetrameric receptor complex (Massague, 1998). TβRII  receptor gets autophosphorylated, 
the mechanism of which is still unclear. TβRII receptor kinase  induce phosphorylation of 
multiple serine threonine residues of the cytoplasmic region of TβRI and in turn the 
phosphorylation of the receptor regulated Smads (R-Smads), Smad2 and Smad3 
(Massague, 1998). The phosphorylation causes Smads to dissociate from the Smad 
anchor for receptor activation (Tsukazaki et al., 1998) and increases their affinity for the 
common partner Smad4 (Chacko et al., 2001). This Smad heteromeric complex then 
translocates into the nucleus by an importin mediated mechanism (Xiao et al., 2000; Xiao 
et al., 2001) or by binding to components of the nuclear pore complex (Xu et al., 2002). 
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The complex can bind directly or indirectly through specific DNA binding proteins, 
resulting in positive or negative regulation of the transcription of various target genes 
(Feng & Derynck, 2005; Massague et al., 2005). The inhibitory Smads, Smads6 and 7, 
can competitively bind to the activated TβRI and inhibit signaling through this pathway 
(Hayashi et al., 1997; Imamura et al., 1997).  Once the response is achieved, all Smads 
except Smad4 are turned off mainly by ubiquitin mediated degradation (Izzi & Attisano, 
2004). 
TGF β1 was initially thought to be a mitogen (Moses et al., 1981; Roberts et al., 1981; 
Ridley et al., 1989) and was later found to have inhibitory effect on cell growth in 
different cell cultures (Shipley et al., 1985). It acts as either a positive or negative 
regulator of cell differentiation depending on the cell type and the physiological state 
(Huang & Huang, 2005). TGF β1 induces squamous differentiation in human bronchial 
epithelial cells (Masui et al., 1986) and also play a role in the differentiation of rat kidney 
fibroblasts to cartilage-like cells (Seyedin et al., 1986). TGF β1 is also shown to mediate 
differentiation in pregnant mouse mammary glands (Yamamoto et al., 1994). On the 
other hand it can act as an inhibitor of differentiation in various systems. For example, it 
is an inhibitor of myogenic differentiation (Massague et al., 1986) and adipogenic 
differentiation of 3T3 fibroblasts (Ignotz & Massague, 1985).  
The anti-proliferative effect of TGF β1 is mediated generally by its ability to modulate 
the expression levels of various proteins that play an important role in the G1 to S phase 
transition during the cell cycle progression. The actual proteins affected might vary with 
the particular cell type (Ten Dijke et al., 2002). Up regulation of cyclin dependent kinases 
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(CDKs) is important in the progression of cell cycle and TGF β1 is shown to up regulate 
the expression of 2 CDK inhibitors namely p15 (p15Ink4b) (Hannon & Beach, 1994) and 
p21 (p21Cip1) (Datto et al., 1995). It can also alter the transcription of genes like c-Myc 
(Pietenpol et al., 1990; Chen et al., 2001; Frederick et al., 2004), CDK activating 
phosphatase, cdc25a (Iavarone & Massague, 1997). Also, TGF β can signal through 
Smad independent pathways that recruit phosphatidylinositol 3-kinase and members of 
mitogen-activated protein kinase (MAPK) (Atfi et al., 1997; Verrecchia et al., 2001; 
Derynck & Zhang, 2003). 
In the lung, the studies on TGF β1 have so far focused on its role in the pathogenesis of 
idiopathic pulmonary fibrosis (Border & Noble, 1994; Corrin et al., 1994; Selman & 
Pardo, 2003; Xu et al., 2003; Venkatesan et al., 2004) and in lung development (Serra et 
al., 1994). The activation of TGF β signaling increases the deposition of extracellular 
matrix components (ECM), which is considered to be the hallmark of fibrosis (Keane et 
al., 2005). Up regulation of TGF β1 mediated through integrin αvβ6 is reported in 
bleomycin-induced  pulmonary fibrosis (Sheppard, 2001). In cultured AEC II cells, TGF 
β1 can inhibit the proliferative effects of KGF (Zhang et al., 2004).  AEC II exposed to 
hyperoxia undergoes a proliferative phase with concurrent down regulation of TGF β3 
(Buckley et al., 1996). Recently, TGF β1 has been shown to inhibit alveolar development 
in new born mouse lung exposed to hypoxia (Ambalavanan et al., 2008), but the presence 
of TGF β1 and Smads in alveolar epithelial cells and their potential role in controlling the 
AEC II- AEC I trans-differentiation process have not yet been reported. 
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1.3 FETAL LUNG DEVELOPMENT 
Fetal lung development, like the development of any other organ, is a tightly regulated 
and complex process. The development of lung can be divided into five different stages 
namely, the embryonic stage, pseudoglandular stage, canalicular stage, saccular stage and 
alveolar stage (Burri, 1984) 
After the primitive gut is formed, lung develops as an outpouch from the ventral wall of 
the future esophagus initiating the embryonic phase of lung development (days 0-13 in 
rat). The epithelial component of the lung is therefore derived from the fore gut 
endoderm and the surrounding connective tissue evolve from the mesoderm. The 
separation of the bud from the gut and the fusion of laryngeotracheal groove enable these 
buds to grow rapidly into the mesenchyme by successive dichotomous divisions distal to 
the gut. Subsequently, lobar and segmental portions of the airway are formed as tubular 
structures lined by columnar epithelium. The vascular connections begin to develop 
during this stage with pulmonary arteries forming a vascular plexus which initially 
connects to the systemic veins and then the capillaries are formed which connects to the 
pulmonary veins.  By the end of the embryonic stage four distinct lung veins open to the 
right auricle of the lung. The lung begins to resemble a tubulo-acinar gland and enters the 
next stage, namely, the pseudo glandular stage (days 13-18 in rat). Two main events 
occur during this stage: formation of all the prospective conducting airways and 
appearance of acinar tubules (Kitaoka et al., 1996). Airway tubes proximally become 
lined by the large columnar cells and distally by cuboidal cells. Differentiated cell types 
like ciliated, non-ciliated, basel and goblet cells appear during this stage. Cartilage and 
smooth muscle cells begin to appear around the trachea. Close relationships develop 
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between the airways and the blood vessels to facilitate future gaseous exchange (Burri, 
1984).  
The canalicular stage (days 18-20 in rats) is characterized by the early development of 
pulmonary parenchyma. The acinus from the earlier stage seems to be newly delineated 
and future terminal and respiratory bronchioles with clusters of small tubules and buds 
are seen during this period.  There is lengthening of each tubular branch and widening of 
the distal airspaces. Capillaries begin to form close contact with overlying cuboidal 
epithelium in each acinus.  There is appearance of lamellar bodies in AEC II cells 
Subsequently at these contact points the cells become flatter, leading to the first 
appearance of an air-blood barrier. This phenomenon is seen peripherally as the terminal 
epithelium is essential for further branching.  This trans-differentiation of cuboidal cells 
to the flat AEC I cells ensures that the air blood barrier undergoes proper development 
and is ready by the time of birth for gaseous exchange (Burri, 1984) 
Saccular stage (day 20-full term) is characterized by the formation of thin walled terminal 
sac. These, in turn, branch into alveolar ducts and alveolar sacs. During this period, a  
significant increase in future respiratory air spaces with subsequent decrease in the 
interstitial tissue is seen. This facilitates the proper orientation of capillaries around each 
developing air space. Elastin deposition around these airways is also initiated and is 
indicative of the beginning of formation of alveoli (Mitchell et al., 1990).  The blood 
vessels become more organized and increase both in diameter and length (Burri, 1984).  
At the beginning of the alveolar stage (from full term to postnatal) the walls of the air 
spaces (primary septa) become thicker with a central sheet of connective tissue flanked 
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on both sides by capillary networks. This is followed by the formation of the secondary 
septa which partitions the saccules into alveolar ducts and sacs (Burri et al., 1974). There 
is remarkable and considerable reduction in the interstitial tissue separating airspaces. 
The alveoli develop their classical appearance with ridges and crests evolving from the 
previously smooth linings of the airspace. The lung progressively prepare for efficient 
gaseous exchange during this period (Burri, 1984; Massaro & Massaro, 1996). 
 Spatial and temporal cascades of signaling through a multitude of pathways ensure that 
appropriate, co-ordinated fetal lung development takes place. Even though many of these 
pathways and their components are studied in lung development, the precise mechanisms 
that fine tune the multiple events during development are still not  fully understood. For 
example, the trigger for primary bud induction from foregut endoderm is poorly 
understood (Cardoso, 2001). Also factors that determine the left-right asymmetry of the 
lung which leads to more number of lobes being formed in the right lung than the left is 
poorly understood. Remarkably, this fate is determined even before the lung buds are 
formed.  
Mesenchymal-epithelial interactions are important events in fetal lung development. 
Various signaling pathways have been studied in this context. Fibroblast growth factor 
family members (FGF) are known mediators of not only this interaction but also in 
branching morphogenesis and cellular differentiation process (Shannon, 1994; Shannon 
et al., 1998).  The most thoroughly studied signaling molecule in lung development, 
arguably, is FGF-10 (Bellusci et al., 1997). The signaling by FGF-10 from the mesoderm 
is critical for the formation of bronchi as evident from a targeted deletion study where 
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FGF-10 knock out mice had trachea, but no bronchi or lung parenchyma (Min et al., 
1998).  Another member of this family namely FGF-7 (KGF, keratinocyte growth factor), 
is known to act as a proliferation factor for lung epithelium (Post et al., 1996). 
In the distal branching morphogenesis, a secreted protein named sonic hedgehog (Shh) is 
found to have an important role (Hogan, 1999). Shh increases mesenchymal proliferation 
and alters the expression of FGF-10. Knockout of the Shh gene results in a lung 
remaining as a rudimentary sac with reduced mesenchymal proliferation and increased 
FGF-10 expression. However, the proximal-distal differentiation seems to be, 
remarkably, unaffected (Pepicelli et al., 1998; de Vries et al., 2005).  
The members of TGF-β family play an important role in lung morphogenesis. TGFβ 1 
reduces branching and saccular bud formation in in vitro lung cultures (Serra et al., 
1994). Knockout of TGFβ3 delays lung development and decreases the SP-C expression, 
an indication of defective AEC II formation and surfactant synthesis (Kaartinen et al., 
1995). Another member of this family, BMP4 influences type II cell formation and the 
rate of epithelial cell proliferation during development (Bellusci et al., 1996).  
A variety of transcription factors are also involved in lung development (Mendelson, 
2000). The members of the Gli family, Gli1, Gli2 and Gli3 (Grindley et al., 1997), 
retinoid receptors, members of the N-myc family (Stanton et al., 1992), thyroid 
transcription factor (TTF1/Nkx2.1) (Kimura et al., 1996), hepatocyte nuclear factor 3β 
(HNF-3β) (Chen et al., 1998), glucocorticoid receptor (GR) (Odom et al., 1988), cyclic 
AMP response element-binding protein (CREB) (Botas et al., 1998) are all known to 
modulate various events in branching and differentiation of fetal lung. 
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The importance of most of these factors was established by loss-of-function studies 
where the knockout of a specific gene resulted in developmental abnormalities. But the 
regulatory mechanisms that govern the spatial and temporal regulation of the majority of 
these signaling molecules are still poorly understood. To untangle the intricate web of 
signaling and to decipher the mechanisms of various levels of control that are put in place 
to orient organ development in the right direction is a challenging task in itself. This 
makes solving the puzzle of development regulation a more complex and dynamic field 
of study.  
In many diseases that affect the normal development of lung, many of these pathways or 
their control mechanisms might be affected. This, in turn, can lead to numerous defects 
that affect the normal functioning of both prenatal and postnatal lung. Dysregulation of 
developmental pathways can either be a cause or an effect for the manifestation of 
diseases.  This can also act in tandem with other contributing factors, leading to the 
disease process.  
1.4 BRONCHOPULMONARY DYSPLASIA 
Bronchopulmonary dysplasia (BPD) is the most common form of chronic lung disease in 
infants. The cause of BPD is multifactorial and involves factors like the immaturity of 
lung due to pre-term birth, complications due to mechanical ventilation leading to 
barotrauma and volutrauma, oxidant injury and treatment using pro-inflammatory 
mediators (Northway et al., 1967; Groneck & Speer, 1995; Van Marter et al., 2000; Jobe 
& Ikegami, 2001; Turunen et al., 2006). The steps taken to help extremely low birth 
weight neonates like positive pressure ventilation actually contribute to the manifestation 
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of this disease. The infants suffering from severe forms of this disease are prone to 
serious respiratory infections and lower lung functions from early childhood.  In many 
cases this can have some affect on proper neural development (Vohr et al., 2004; 
Ehrenkranz et al., 2005). The risk of developing BPD increases with a decrease in birth 
weight and gestational age. For neonates with birth weights between 700-900 gram, the 
chance of developing BPD is almost 50% while that for neonates with weight over 1250 
gram is less than 5% (Avery et al., 1987). In earlier days, BPD was characterized as a 
severe and chronic disease with significant fibrosis and cellular proliferation (Kunig et 
al., 2005). The lesions in this ‘old’ BPD pathology were manifested due to hyperoxia 
resulting from positive pressure ventilation on an immature and surfactant deficient lung 
(Coalson, 2006). This included damage to airway epithelia, smooth muscle hyperplasia, 
areas of atelectasis or over inflation, fibrosis and vascular lesions (Bonikos et al., 1976). 
The advent of new treatment methodologies like exogeneous surfactant administration, 
improved ventilation strategies, better nursing techniques in neonatal intensive care units 
and new antenatal treatment regimes using steroids have altered the clinical progression 
and lung histology of BPD (Coalson, 2006). This ‘new’ BPD pathology is less severe and 
terms like ‘neonatal chronic lung disease’ has been coined to include this new less severe 
form of BPD so as to encompass the complete spectrum of ‘new’ BPD (Hyde et al., 
1989).   
In this new and milder form of BPD which manifests in more immature infants, the 
primary cause for the pathogenesis is not oxidative injury and mechanical ventilation, but 
the immaturity of the developing lung that has been forced to undergo gaseous exchange 
without completing proper development.  The ‘new’BPD pathology is characterized by 
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decreased, large and simplified alveoli, decreased dysmorphic capillaries, negligible 
airway epithelial lesions, variable interstitial fibro-proliferation and variable airway 
smooth muscle hyperplasia (Coalson, 2003). The only consistent change in the ‘new’ 
BPD pathology is the alveolar simplification and enlargement of alveoli (Coalson, 2003). 
This results from the impairment in postnatal alveolarization in an immature lung due to 
preterm birth and not due to the arrest of development (Husain et al., 1998; Coalson, 
2003). The ‘new’ BPD model may also include abnormal distribution of capillaries, 
stunted secondary septation and abnormal microvasculature (De Paepe et al., 2006). Also 
experimental treatments such as hyperoxia, hypoxia, lack of nutrition and glucocorticoid 
administration are shown to decrease septation as seen in ‘new’BPD (Massaro & 
Massaro, 1996). Elastogenesis, an essential process in alveolar septation is also thought 
to be hampered in BPD (Bruce et al., 1992; Bourbon et al., 2005). The molecular 
mechanisms that cause the stunted lung growth and abnormal alveolar septation in BPD 
are poorly understood.  Disturbing the normal angiogenesis using anti-angiogenic agents 
results in the formation of lung structures as seen in ‘new’ BPD (Jakkula et al., 2000; 
Kunig et al., 2005). Inhibition of signaling through vascular endothelial growth factor 
(VEGF) receptor also shows the same kind of lesion (Jakkula et al., 2000; Le Cras et al., 
2002). Also hyperoxia causes impaired VEGF signaling and is thought to contribute to 
the pathology of BPD (Lassus et al., 2001; Afshar et al., 2003). Bombesin-like peptides 
(BLP) produced by neuroendocrine cells are increased during experimental induction of 
BPD in primate models and are also thought to mediate the disease process (Sunday et 
al., 1998). Gene expression profiling in experimental BPD has been done in an animal 
model that shows ‘old’ BPD pathology (Wagenaar et al., 2004). As a result there were 
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more changes in the inflammatory mediators like interleukins. But in stages where 
reduction in secondary septation and alveolar enlargement were observed, there was 
downregulation of fibroblast growth factor receptor-4 (FGF-4) (Wagenaar et al., 2004). 
This is consistent with the data from FGF-4 (-/-) knock out mice which are normal at 
birth but have complete lack of alveogenesis and formation of secondary septum 
(Weinstein et al., 1998). There was a decrease in VEGF receptor-2 expression which is 
known to cause alveolar septal cell apoptosis and defective alveolar development 
(Kasahara et al., 2000). Abnormal expression of other developmentally important factors 
like FGF-7 (KGF) (Das & Ravi, 2004) and insulin like growth factors (IGF) I and II 
(Veness-Meehan et al., 1997) have also been reported in BPD. 
Several animal models have been used to study BPD. Each model has given us different 
insights into the development of BPD. The lamb model developed by Bland et al has 
given valuable insights into changes in pulmonary circulation and fluid imbalance (Bland 
et al., 2000). The baboon model was developed to study the ‘old’BPD  (Coalson et al., 
1982; Escobedo et al., 1982). Many surfactant treatment studies were standardized in this 
model as it closely resembles the humans. Also there are rat and mouse models for BPD 
(Bonikos et al., 1975; Han et al., 1996). Like in baboons and unlike in lambs, there is 
postnatal alveolarization which continues for 14 days after birth in both rat and mice 
(Coalson, 2006). Lesions corresponding to both ‘old’ and ‘new’ BPD can be manifested 
by changing the concentration of oxygen to which they are exposed and the stage at 
which they are exposed (Bonikos et al., 1975; Pappas et al., 1983; Han et al., 1996; 
Warner et al., 1998). The data from all these models have been compared and used to 
13 
draw conclusions about the common factors and lesions associated with both forms of 
BPD even though much remains unknown. 
1.5 MICRORNAS 
MicroRNAs are small RNAs ~21-24 nucleotides in length and endogeneous in origin. 
They are transcribed from genes, but not translated to any proteins. They suppress protein 
expression by cleavage of mRNA or translational suppression (Bartel, 2004).  miRNAs 
were discovered in 1993 by Ambros and his colleagues in the nematode Caenorhabditis 
elegans (Lee et al., 1993). The down-regulation of LIN-14 protein is essential for the 
progression from 1st larval stage (L1) to the next (L2) in this organism. It was found that 
the transcription of lin-4 gene was essential for this downregulation to occur. More 
importantly the transcription of lin-4 did not result in a protein, but in two small RNAs, 
one ~21 nucleotide in length and the other ~61 nucleotide in length. The longer one could 
form a stem-loop structure and act as the precursor for the shorter one. Later this group 
along with Wightman et al found that the smaller RNA had anti-sense complimentarity to 
multiple sites in the 3’UTR of lin-14 mRNA (Lee et al., 1993; Wightman et al., 1993). It 
was also observed that binding between these complimentary regions decreased the 
expression of LIN-14 protein without significant change in the level of lin-4 mRNA 
(Wightman et al., 1993). These two studies together brought forth a model where there is 
base pairing between multiple lin-4 RNAs to the complimentary sites in the 3’UTR of 
lin-14 mRNA thereby causing translational repression of lin-14 and subsequent 
progression from L1 to L2 during C. elegans development. This new kind of regulation 
was first thought to be a phenomenen exclusive to C. elegans.  In 2000, two separate 
groups discovered another small RNA, let-7, which was essential for the development of 
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a later larval stage to adult (Reinhart et al., 2000; Slack et al., 2000). More importantly, 
homologues of this gene were discovered in many other organisms including human 
beings (Pasquinelli et al., 2000). Within a shorter period of time, multiple labs cloned 
small RNAs from humans, flies and worms. These RNAs were non coding , ~ 22 
nucleotides in length and seemed to derive from a longer precursor with a stem-loop 
structure (Bartel, 2004). Many of them were conserved evolutionarily and exhibited cell 
type specificity. The recognition and confirmation of the existence of these small RNAs, 
termed microRNAs (miRNAs), led to intensive research to identify new members of this 
family. This has resulted in the discovery of multiple  miRNAs across different species of 
both plants and animals. A miRNA registry was also set up where all the newly identified 
miRNAs. Named miRBase, this registry presently contains 6396 entries of potential 
miRNAs (Griffiths-Jones, 2004). Many of these miRNAs are still unverified at a 
functional level. 
A majority of the miRNAs are transcribed from regions distant from the previously 
known genes (Lagos-Quintana et al., 2003). Earlier studies indicated that many miRNA 
genes were located in the introns of pre-mRNAs, did not have their own promoters and 
were in the same orientation as the predicted mRNAs (Lagos-Quintana et al., 2003; Lai et 
al., 2003; Lim et al., 2003). New studies have revealed that almost 70% of mammalian 
miRNA genes are located in specific and defined transcription units (Rodriguez et al., 
2004). Clusters of miRNA genes have also been discovered with a potential to be 
transcribed as a single unit (Lau et al., 2001; Lagos-Quintana et al., 2003) although this a 
very small minority among all known miRNA genes. Since this is a relatively new and 
rapidly evolving field, there is potential for new insights to significantly overhaul the 
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current knowledge. From the current body of knowledge, it can be said that miRNAs can 
be present on diverse locations within a genome. This paves the way for a wide array of 
miRNA expression scenarios which greatly enhances the potential for gene regulation in 
multiple ways.   
The biogenesis of miRNAs is initiated by the transcription of the primary miRNA (pri-
miRNA) which is hundreds of nucleotides long. The pri-miRNA is then processed into 
~70 nucleotide precursor RNA (pre-miRNA) by a nuclear RNase III enzyme called 
drosha (Lee et al., 2003). This 160 kDa protein is conserved in animals and not in plants 
(Wu et al., 2000). It needs a cofactor known as DiGeorge syndrome critical region gene 8 
(DGCR8) in humans or Pasha in insects and worms (Denli et al., 2004; Gregory et al., 
2004; Han et al., 2004; Landthaler et al., 2004). This pre-miRNA which has a typical 5’ 
phosphate and ~2 nt 3’ overhang is then exported into the cytoplasm through Ran-
dependent nuclear transport receptor named exportin-5 (Exp5) (Yi et al., 2003; Lund et 
al., 2004). In the cytoplasm the pre-miRNAs are processed into mature  ~22 nucleotide 
long duplexes by another RNase III enzyme called dicer (Lee et al., 2002; Yi et al., 
2003). Like drosha, dicer is highly conserved and needs binding with a partner to elicit its 
effect (Chendrimada et al., 2005). The mature miRNAs are then taken up into micro 
ribonuclear protein complexes (miRNPs) also called RNA induced silencing complexes 
(RISC). The strand with loose pairing at the 5’ end remains incorporated while the other 
is degraded (Schwarz et al., 2003).  
The mechanism by which miRNAs downregulate gene expression is thought to vary 
depending upon the degree of complementarity between the miRNA and the target 
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regions in the mRNA.  Sufficient complementarity is believed to degrade mRNA while a 
lower complementarity leads to translational suppression (Hutvagner & Zamore, 2002). 
But there are exceptions where even near perfect complementarity leads to translational 
suppression but not cleavage (Aukerman & Sakai, 2003). Recently, another mechanism 
of action has been proposed where binding of miRNAs lead to faster deadenylation of 
mRNAs thereby accelerating their degradation (Wu et al., 2006).  
miRNAs are now believed to be major players in regulating various biological processes 
ranging from development of organs to virus invasion. Embryonic stem cell 
differentiation, a cardinal event in the development of any organ or organ system, is now 
thought to be modulated by miRNAs.  The knock down of dicer in fruit flies caused 
embryonic lethality with abnormal morphology and significant lack of stem cells 
(Kloosterman & Plasterk, 2006). In mice, even though dicer deficiency did not stop the 
formation of stem cell colonies, it severely impaired the differentiation capability of 
embryonic stem cells and caused defect in the cellular morphology (Kanellopoulou et al., 
2005). Even in somatic stem cells, this holds true, where dicer deficiency has led to 
developmental defects in limb and hair follicles (Kloosterman & Plasterk, 2006). Even 
though the roles of individual miRNAs are still not clearly defined, these studies 
demonstrate that right from early development the miRNAs might be playing an 
important role in determining the developmental fate of an organism. 
Recent studies have identified several miRNAs that play a major role in the proper 
development of various organ systems. miR-273 has been found to be important in 
establishing left-right assemmetry during neuronal development (Hobert, 2006). A 
17 
remarkable observation was seen in heart, where even partial deletion of miR-1-2 caused 
severe and fatal defects in cardiac morphology (Zhao et al., 2007).  miR-208 deletion 
caused abnormal response of heart to stress (van Rooij et al., 2007). In immune system, 
miR-155 down regulation caused defects in adaptive immunity response with increased 
fibrosis and infiltration in lung (Rodriguez et al., 2007) while miR-150 deletion altered 
normal lymphocyte production (Xiao et al., 2007).  Another important functional role 
was seen in insulin secretion where miR-375 expression in pancreatic islets directly 
altered exocytosis of insulin from pancreatic beta cells (Poy et al., 2004).  Various 
miRNAs have now been implicated in modulation of a range of functions like adipocyte 
differentiation (Esau et al., 2004), balancing proliferation and apoptosis (Brennecke et al., 
2003; Cheng et al., 2005) and lipid metabolism (Esau et al., 2006).  Progression of 
various forms of cancers have also been found to be modulated by miRNAs 
(Takamizawa et al., 2004; He et al., 2005b; Yanaihara et al., 2006; Blenkiron & Miska, 
2007). They can either act as oncogenes or tumor supressors (Cowland et al., 2007).  
Examples of miRNAs as tumor suppressors include miR-15, miR-16 (Calin et al., 2002) 
and let-7 family members (Johnson et al., 2005). Oncogenic miRNAs include miR-155 
(Eis et al., 2005; Yanaihara et al., 2006) and the miRNA cluster miR-17-92 (He et al., 
2005a). Another interesting role for miRNAs is seen in virus invasion where viruses like 
HIV-1 supress silencing mediated by miRNAs during their replication in host cells 
(Triboulet et al., 2007).  Many viruses are also thought to make miRNAs that faciliate 
their invasion into host cells. Many of the knock out studies that were done to study the 
function of various genes would have invariably included deletion of introns. Since  a 
significant number of miRNAs is known to be present in introns, the loss of miRNAs 
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might also be a contributing factor to the phenotypic consequences seen in these 
individual knockout studies (Osokine et al., 2008). Taken together, the current knowledge 
in this rapidly advancing area of research reiterates the notion that miRNAs are major 
players in the regulation of a wide array of biological processes ranging from 
development to disease. 
In both development and diseases in lung, miRNA studies have been very limited. Dicer 
knockout has been shown to impair lung morphogenesis (Lu et al., 2005; Harris et al., 
2006).  miRNA let-7 has been implicated in the progression of lung cancer (Takamizawa 
et al., 2004). The only study in lung development, to date, has shown that overexpression 
of miR-17-92 cluster resulted in enhanced proliferation and reduced differentiation of 
epithelial progenitor cells in the developing lung (Lu et al., 2007).  
1.6 OBJECTIVES 
The objectives of the present dissertation are as follows: 
1. To elucidate the role of TGF β1 mediated signaling in alveolar epithelial trans-
differentiation 
The current study examines in detail the role of TGF β1 mediated signaling in the 
trans-differentiation of AEC II to AEC I and to see whether the signaling is Smad-
dependent. The study also proposes a probable pathway through which their action 
might be elicited.  
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2. To identify and characterize miRNAs that modulate fetal lung development 
Since miRNAs are now regarded as important mediators of development and disease, 
profiling the expression pattern of miRNAs during lung development will give us 
better insights into new levels of regulation of this process. This study examines 
miRNA expression pattern during fetal lung development and validates the 
expression profile of selected miRNAs. miRNAs which show significant and 
interesting trends of expression were chosen for further studies so as to assign 
functionality to them 
3. To establish a rat model of BPD and profile the miRNAs those are significantly 
changed in BPD 
This study also aims at establishing a rat model for BPD where the pathology 
corresponds to that described for‘new’ BPD.  Using this model, the miRNAs that are 
significantly changed in BPD will be profiled and the changes confirmed. This will 
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CHAPTER II 
TRANS-DIFFERENTIATION OF ALVEOLAR EPITHELIAL TYPE II CELLS TO 
TYPE I CELLS INVOLVES AUTOCRINE SIGNALING BY TGF ß1 THROUGH THE 
SMAD PATHWAY 
ABSTRACT 
Type II Alveolar Epithelial Cells (AEC II) proliferate and trans-differentiate into Type I 
Alveolar Epithelial Cells (AEC I) when the normal AEC I population is damaged in the 
lung alveoli. We hypothesized that signaling by Transforming Growth Factor β1 (TGF 
β1), through its down stream Smad proteins, is involved in keeping AEC II quiescent in 
normal cells and its altered signaling may be involved  in the trans-differentiation of AEC 
II to AEC I. In the normal lung, TGF β1 and Smad4 were highly expressed in AEC II.  
Using an in vitro cell culture model, we demonstrated that the trans-differentiation of 
AEC II into AEC I-like cells began with a proliferative phase, followed by a 
differentiation phase. The expression of TGF β1, Smad2 and Smad3 and their 
phosphorylated protein forms, and cell cycle inhibitors, p15Ink4b and p21Cip1 was lower 
during the proliferative phase but higher during the differentiation phase. Furthermore, 
cyclin dependent kinases 2, 4 and 6 showed an opposite trend of expression. TGF β1 
secretion into the media increased during the differentiation phase, indicating an 
autocrine regulation. The addition of TGF β1 neutralizing antibody after the proliferative 
phase and silencing of Smad4 by RNA interference inhibited the trans-differentiation 
process. In summary, our results suggest that the trans-differentiation of AEC II to AEC I 
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is modulated by signaling through the Smad-dependent TGF β1 pathway by altering the 
expression of proteins that control the G1 to S phase entry in the cell cycle.  
INTRODUCTION 
Alveolar Epithelial cells (AEC II) have a multifunctional role in the lung including 
secretory, synthetic and progenitor capacities.  AEC II serve as remodeling reservoirs for 
lung epithelium (Warburton and Bellusci, 2004). They are the progenitors for AEC I. By 
virtue of their squamous shape, AEC I cover the major surface area of alveoli and thus 
are the main epithelial component of the thin air-blood barrier. In contrast, AEC II are 
limited to the corners of the alveoli. The progenitor function of AEC II is activated when 
the lung epithelium encounters a variety of disease conditions including acute lung injury 
(Fehrenbach, 2001). AEC II cell proliferation and hyperplasia, followed by trans-
differentiation into AEC I is a hallmark of alveolar epithelial injury. This helps to restore 
the normal air-blood barrier. However, the molecular mechanisms involved in the trans-
differentiation process are not clear. Questions regarding the causes of AEC II 
proliferation and trans-differentiation into AEC I during lung injury and prevention of 
this in normal alveoli largely remain unanswered.  
The Transforming Growth Factor β (TGF β) superfamily consists of cytokines that are 
implicated in the regulation of a variety of biological responses (Li et al., 2006; 
Massague, 2000; Moustakas et al., 2001; ten Dijke et al., 2002). Its members include 
isoforms of TGF β, bone morphogenetic proteins, Mullerian inhibiting substance, 
inhibins and activins. A member of this family, TGF β1, regulates cell proliferation, 
differentiation and migration in many cell and tissue systems. This cytokine is secreted 
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by various cell types and acts both in autocrine and paracrine manners. The binding of 
TGF β1 to its specific type II receptor (TβRII) induces the formation of a hetero 
tetrameric complex with the type I receptor (TβRI). This complex phosphorylates the 
TβRI. The activated TβRI  in turn phosphorylates the receptor-regulated Smads (R-
Smads),  Smad2 and Smad3. The phosphorylated R-Smads disassociate with the Smad 
anchor for receptor activation (SARA) (Tsukazaki et al., 1998) and assemble with the 
common partner Smad (Co-Smad) named Smad4. The Smad heteromeric complex 
translocates into the nucleus, binds to DNA directly or indirectly through specific DNA 
binding proteins, and regulates the transcription of target genes (Feng and Derynck, 2005; 
Massague et al., 2005) Also there are inhibitory Smads (I-Smads), Smad6 and Smad7, 
which are antagonistic to the R-Smads and act by competitively binding to the activated 
TβRI (Hayashi et al., 1997; Imamura et al., 1997). Once the response is achieved, R-
Smads and I-Smads are turned off  mainly by ubiquitin-mediated degradation (Izzi and 
Attisano, 2004).  
The mechanism by which TGF β inhibits cell proliferation varies in different epithelial 
cells (ten Dijke et al., 2002). Generally, the action is elicited by altering the levels of cell 
cycle proteins that are involved in the G1 to S phase entry before the restriction point in 
the cell cycle. TGF β  increases  the expression of two cyclin dependent kinase inhibitors, 
p15 (p15Ink4b) (Hannon and Beach, 1994) and p21 (p21Cip1) (Datto et al., 1995), which in 
turn inhibit Cyclin Dependent Kinases (CDKs) 2, 4, and 6. TGF β can also inhibit the 
transcription of genes needed for the cell cycle progression. This includes c-Myc (Chen et 
al., 2001; Frederick et al., 2004; Pietenpol et al., 1990) and CDK activating phosphatase, 
cdc25A (Iavarone and Massague, 1997). Additionally, TGF β can initiate signaling 
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through pathways other than those involving Smads, such as PI3 kinase and various 
members of the mitogen activated protein kinase (MAPK) (Atfi et al., 1997; Derynck and 
Zhang, 2003; Verrecchia et al., 2001).  
Although several studies have shown that TGF β1 has a role in modulating abnormal 
lung conditions such as idiopathic pulmonary fibrosis (IPF) (Corrin et al., 1994; Selman 
and Pardo, 2003; Venkatesan et al., 2004; Xu et al., 2003), whether it controls AEC II 
proliferation and trans-differentiation into AEC I has not been examined in detail. Studies 
on the effect of TGF β1 on AEC II so far have been limited to its anti-proliferative effects 
on culture systems that maintain the AEC II phenotype (Zhang et al., 2004). Here, we 
report the role of Smad-dependent TGF β1 pathway in the trans-differentiation of AEC II 
to AEC I using a model that mimics the differentiation process that takes place during 
lung injury.  Through the addition of TGF β1 and its neutralizing antibody, RNA 
interference (RNAi)-mediated silencing of Smad4 and by showing differential expression 
of the components of TGF β pathway and cell cycle proteins during the trans-
differentiation process, we have demonstrated a possible mechanism of controlling this 
process in the alveolar epithelium.   
MATERIALS AND METHODS 
Rat IgG, deoxyribonuclease 1, n-propyl gallate, 5-bromo-2’-deoxy uridine and 
recombinant human TGF β1 were obtained from Sigma Aldrich (St. Louis, MO). Elastase 
was from Worthington Biochemical Corporation (Lakewood, NJ). Mouse monoclonal 
anti-Smad4, goat polyclonal anti-p15, anti-p21, anti-CDK2, anti-CDK4, anti-CDK6, goat  
polyclonal anti-purinergic receptor P2X7 (P2X7) and  anti-surfactant protein C (SP-C) 
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antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal 
anti-Smad2, rabbit polyclonal anti-pSmad2 and anti-pSmad3 antibodies were from Cell 
Signaling Technology (Danvers, MA). Rabbit polyclonal anti-Smad3 was from Abcam 
(Cambridge, MA). Monoclonal anti-TGF β1 antibody and mouse/rat/porcine TGF β1 
Quantikine ELISA Kit were from R & D systems (Minneapolis, MN). Mouse anti-LB-
180 antibody was from Covance (Berkeley, CA). Alexa 568- and 488-conjugated anti-
rabbit and anti-mouse secondary antibodies were from Molecular Probes (Eugene, OR). 
Cy3-conjugated affini pure goat anti-mouse IgG was from Jackson Immuno Research 
Laboratories (West Grove, PA). The Dc protein assay kit and horse-radish peroxidase 
(HRP)-conjugated anti-mouse antibodies were from BioRad (Hercules,CA). The 
enhanced chemiluminescence detection system was from Amersham Biotech 
(Piscataway, NJ). Anti-rat and anti-mouse IgG-conjugated magnetic beads were from 
Dynal Biotech (Lake success, NY). The TRI reagent was from Molecular Research 
Center Inc. (Cincinnati, OH). M-MLV Reverse transcriptase was from Invitrogen 
(Carlsbad, CA). DNA polymerase was from New England Biolabs (Beverly, MA). 
Quantitect SYBR Green PCR kit was from Qiagen (Valencia, CA). Penicillin, 
streptomycin and fetal bovine serum (FBS) were from Gibco (Grand Island, NY). 
Dulbecco’s Modified Eagles Medium Hams Nutrient Mixture F-12 (DMEM/F-12) in 1:1 
ratio was from ATCC (Manassas, VA).  
Isolation and culture of AEC II 
AEC II were isolated from pathogen free male Sprague-Dawley rats (200-250g) by an 
improved method as  previously described (Chen et al., 2004a). In brief, adult rat lungs 
were perfused, lavaged and digested with elastase (3 units/ml). The cell mixture was 
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filtered through 160- and 37-µm nylon mesh once and 15-µm nylon mesh twice, and 
plated on rat IgG-coated plates twice for 45 and 30 min to remove macrophages. The 
unattached cells were further incubated with anti-Leukocyte Common Antigen (anti-LC, 
40 µg/ml) and rat IgG (70 µg/ml) antibodies for 30 min at 40C. This was followed by 
incubation for 20 min with anti-rat and anti-mouse IgG-conjugated magnetic beads. A 
magnetic field was applied to remove the cells attached to the magnetic beads. The purity 
of AEC II was above 95% as determined by modified Papanicolaou staining and the 
viability was above 98%. 
AEC II were seeded onto 35 mm tissue culture-treated plastic dishes at a density of 1.3 x 
106 cells per dish in Minimum Essential Medium (MEM) with 10% FBS and cultured for 
1 to 7 days. The media were changed after the first 24 h and thereafter on alternate days. 
In this culture system, the trans-differentiation of AEC II to AEC I-like cells was evident 
from day 3 onwards and was nearly complete by day 5. For the sandwich ELISA 
experiment to quantitate TGF β1 secreted into media, modified serum free medium 
(MDSF) was used. The MDSF contained 1:1 ratio of DMEM/F 12 media, bovine serum 
albumin (1.5 mg/ml), 10 mM HEPES, 0.1 mM non-essential amino acids, 2 mM 
glutamine, 1000 U/mL penicillin G and 100 µg/ml streptomycin.  
Immunohistochemistry and Immunohistochemistry 
Paraffin-embedded tissue sections of perfused rat lungs were de-waxed using xylene and 
rehydrated using descending grades of ethanol. They were then washed in phosphate-
buffered saline (PBS, pH 7.4). Antigen retrieval was done by boiling the slides for 15 min 
in 20 mM citrate buffer (pH 6.0). Cytospinned cells or cells cultured in 35 mm plastic 
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dishes were fixed in 4% paraformaldehyde. The tissue sections or cells were 
permeabilized with 0.4% Triton X-100 for 20 min and blocked for 1 h in 10% FBS. The 
slides were then incubated with mouse anti-Smad4 (1:50), mouse anti-TGF β1 (1:10), 
LB-180 (1:200), SP-C (1:100) or P2X7(1:50) antibodies at 40C overnight. Slides were 
washed and incubated with Alexa 568-conjugated anti-rabbit/anti-goat and Alexa 488-
conjugated anti-mouse/anti-rabbit secondary antibodies or Cy-3-conjugated Affini pure 
anti-mouse IgG (1:250 dilution). Finally, slides were then washed and mounted on an 
anti-fade medium (5% n-propyl gallate and 80% glycerol in PBS) and viewed through a 
Nikon Eclipse E600 fluorescence microscope or Nikon Eclipse TE 2000 U inverted 
fluorescent microscope. 
Real-time PCR 
Total RNA (1 µg) was isolated using TRI reagent and reverse-transcribed into cDNA 
using 200 U of M-MLV reverse transcriptase and a mixture of random and oligo dT 
primers. Gene sequence information was obtained using nucleotide databases 
(www.ncbi.nlm.nih.gov/Entrez). All primer sequences (Table 1) were designed using the 
primer express 2.0 software and confirmed for specificity by using the non-redundant 
basic local alignment search.  
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Table 1  Primers used for real time PCR 
GenBank ID Gene name Primers 

























The reverse transcribed cDNA was further diluted 5 times and quantitative real time PCR 
was done using an ABI prism 7700 system (PE Applied Biosystems, Foster City, CA). 
The reactions were carried out on 96 well plates.  18S rRNA was amplified on the same 
plates and used to normalize the data. The reaction volume was 10 µl containing 5 µl of 
the SYBR master mix, 0.4 µl of 25 mM MgCl2, 0.3 µl each of 5 µM forward and reverse 
primers, 2 µl of RNase free water and 2 µl of the cDNA samples. Each sample was 
prepared in duplicate and at least 3 different sets of cell preparations were used. The 
thermal cycling conditions used were: 95ºC for 15 min followed by 40 cycles at 95ºC for 
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20 sec, 60ºC for 30 sec and 72ºC for 30 sec. The data acquisition temperature varied from 
76 to 78ºC depending on the melting temperature of the individual PCR products. 
Dissociation curve analysis was performed for each gene to ensure the specificity of PCR 
products. The relative abundance of each gene was calculated by subtracting the CT 
value of each sample of an individual gene from the corresponding value for 18S gene 
(delta CT).  Freshly isolated AEC II (Day 0) were used as the reference point. Delta delta 
CT were obtained by subtracting CT of the reference point. These values were raised to 
the power of 2 (2delta delta CT) to give expression levels relative to day 0 expression. 
Western blot 
Cells were lysed in lysis buffer (10 mM Tris-HCl, pH 7.5, 1% Triton X-100, 1 mM 
EDTA and 1 mM phenylmethylsulfonylfluoride, 10 µg/ml aprotonin and 10 µg/ml 
leupeptin). The protein concentration was determined by the Dc protein assay kit.  20 µg 
of protein was separated on 12% SDS polyacrylamide gels, transferred to a nitrocellulose 
membrane using the semidry transfer apparatus (BioRad) at 17 mA for 60 min. The 
membrane was stained with Ponceau S to ensure proper transfer and blocked overnight 
with 5% dry skim milk power in 100 mM Tris-buffered saline plus 0.1% Tween-20 
(TBS-T). The membranes were incubated with anti-Smad2, anti-Smad3, anti-Smad4, 
anti-TGF β1, anti-pSmad2, anti-pSmad3, anti-p15, anti-p21, anti-CDK2, anti-CDK4 or 
anti-CDK6  antibodies at 1:100 dilutions overnight at 4ºC. After being washed in TBS-T 
3 times, the membranes were incubated with horseradish peroxidase-conjugated anti-
mouse, goat or rabbit IgG’s (1:2000) for 1 h. The blots were washed again. The 
individual target proteins were visualized using the enhanced chemiluminescence 
detection system. 
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5-Bromo-2’-deoxy uridine (BrdU) labeling   
To determine cell proliferation in the in vitro AEC trans-differentiation model, BrdU was 
added at a concentration of 10 µM into the culture media and incubated for 12 - 14 h. 
After being washed with PBS (pH 7.4), the cells were fixed with 75% methanol 
containing 5 mM glycine at -200C for 20 min. The cells were washed again and treated 
with 2 M HCl to denature the DNA strands followed by neutralization using borate buffer 
(pH 9.4). The cells then were washed with  PBS containing 0.05% Tween-20 (PBS-T) 
and blocked in 10% FBS in PBS-T for 2 h. BrdU was detected using monoclonal anti-
BrdU Antibody (1:100 dilution) and FITC-conjugated rabbit anti mouse antibody (1:250 
dilution). 
Sandwich ELISA 
To measure the TGF β1 secretion into the media, AEC II were cultured in MDSF on 
plastic dishes for 0 -5 days. The use of MDSF avoids potential contamination from 
endogenous TGF β1 in FBS. The amount of TGF β1 secreted into the medium was 
assayed using an ELISA kit. Briefly, monoclonal anti-TGF β1 antibody was precoated on 
a microplate. The latent TGF β1 in the media was activated by the addition of 1 N HCl, 
followed by neutralization using 1.2 N NaOH/0.5M HEPES. Serially diluted standards, 
controls and activated samples were incubated on the microplate for 2 h at room 
temperature on an orbital shaker. This was followed by thorough washing and the 
addition of HRP-conjugated polyclonal antibody specific to TGF β1. After 2 h of 
incubation and subsequent washing, the substrate solution was added to each well. The 
plate was protected from light and incubated for 30 min at room temperature so that color 
developed in proportion to the amount of TGF β1 bound in the initial step. The reaction 
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was terminated by adding the stop solution. The optical density was measured within 30 
min using a microplate reader set to 450 nm with a wavelength correction set at 540 nm.   
Construction of adenovirus vectors 
A new pK4-shRNA vector, developed in our lab, was used to silence Smad4. The single 
vector expresses four short hairpin RNA (shRNA) driven by four different promoters 
after transfecting into cells. The details for the construction of the new vector will be 
published elsewhere. The four small interfering RNA (siRNA) sequences for Smad4 
were:  
5'-GGTGGAGAGAGTGAGACATT-3' (85-104),  
5'-GCGTCTGTGTGAACCCATATC-3'(374-394), 
5'-GGAATTGATCTCTCTGGATTA-3'(418-428) 
5'-GGAGTGCAGTTGGAGTGTAA A-3' (1156-1176).  
A vector contain four non-relevant siRNA sequences was used as a control. The 





The expression cassettes were ligated into pENTR vectors (Invitrogen) using the 
Invitrogen Gateway® technology. They were switched to the adenoviral vectors by LR 
recombinations. The viral vectors were transfected into 293A cells to produce the first 
generation of virus. After amplification, the second generation of viruses was used to 
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infect target cells. The virus with Smad4 silencing sequence was named AdSmad4Si and 
the control with the four non-relevant sequences AdCon. 
Statistical analysis 
Data was expressed as means ± SE. Statistical analysis was performed by using one way 
ANOVA using the GraphPad Prism software, followed by Dunnett's Multiple 
Comparison Test. The significance was assigned at  p <0.05. 
RESULTS 
TGF β1 and Smad4 were highly expressed in AEC II. 
To identify cellular localization of TGF β1 and Smad4, double-immunolabeling was 
performed on perfused normal rat lung tissue sections by using monoclonal antibodies for 
TGF β1 or Smad4, and goat polyclonal antibody for SP-C (an AEC II marker). The 
results revealed a strong co-localization of both proteins with SP-C in AEC II (Fig. 1). 
The negative controls with only secondary antibodies did not show any signals.  TGF β1 
and Smad4 were also present to a lesser extent in AEC I. A high expression of TGF β1 
was also seen in alveolar macrophages and bronchial epithelial cells. 
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Figure 1 - Immunohistochemistry of rat lung tissue sections for TGF β1 and 
Smad4.  
 Double labeling of rat lung tissue sections was done using anti-TGF β1 and 
anti-SP-C antibodies (Panels a-d) or anti-Smad4 and anti-SP-C antibodies 
(Panels e-h). This was followed by incubation with the corresponding Alexa 
488- or 568-conjugated secondary antibodies. Panel d shows the overlay 
between TGF β1 and SP-C signals while panel h shows the overlay between 
Smad4 and SP-C. The negative control was without primary antibodies (Panels i 
-l). Scale bars: 5 μm. 
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AEC II proliferated and then differentiated to AEC I-like cells in the in vitro trans-
differentiation model.  
It is well known that AEC II gradually trans-differentiate into AEC I-like cells when 
cultured on plastic dishes (Paine and Simon, 1996; Williams, 2003). However, the 
kinetics of cell proliferation and differentiation during this process has not been 
examined. The trans-differentiation of AEC II to AEC I-like cells was confirmed by 
immunostaining with AEC II and AEC I markers, LB-180 for AEC II and P2X7 for AEC 
I (Chen et al., 2004b; Zen et al., 1998). On day 1, LB-180 expression was strong with no 
expression of P2X7, but it disappeared on day 3 and day 5 along with the concurrent 
appearance of P2X7 (Fig. 2A). This indicates that the trans-differentiation occurs 
between day 3 and day 5. Some day 3 cells showed the expression of both AEC II and 
AEC I markers, demonstrating the possibility of an intermediate cell type.   The BrdU 
staining experiments showed that AEC II proliferation increased from day 1 to day 2 and 
decreased thereafter (Fig. 2B). This suggests that there is a proliferation phase (day 0 to 










Figure 2 - Expression of AEC I and AEC II markers and BrdU labeling during the 
trans-differentiation 
A. Double labeling of the cultured cells on days 1, 3 and 5 was done using anti-LB-
180 (panels b, e and h) and anti-P2X7 antibodies (panels c, f and i). The protein 
expression was visualized using corresponding Alexa 488- or 568-conjugated 
secondary antibodies. 
B. BrdU labeling: BrdU was added at a concentration of 10 µM to the culture media 
12-14 hours before cell fixing. Immunostaining was done on the cells cultured for 1-
5 days using anti-BrdU antibody and Alexa 488-conjugated secondary antibody. 
Scale bar: 5 μm. 
mRNA and protein expression levels of TGF β1 and Smads were altered during the 
trans-differentiation from AEC II to AEC I-like cells. 
Since there is a proliferation phase immediately following AEC II isolation and culture, 
we hypothesized that the expression of TGF β1 and its down stream components, R-
Smads would be lower during the proliferation phase, but increase during the 
differentiation phase so as to facilitate the cell cycle exit. We therefore examined the 
mRNA and protein expression levels of TGF β1 and Smads in the in vitro trans-
differentiation model by real time PCR and Western blotting. (The TGF β1 mRNA 
expression level was low during proliferation, but increased significantly during the later 
stage of differentiation (Fig. 3A).  The same trend was observed at the protein level (Fig. 
3B).  
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Figure 3 - The expression and secretion of TGF β1 during trans-differentiation. 
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Figure 3 - The expression and secretion of TGF β1 during trans-differentiation. 
AEC II were seeded on plastic dishes and cultured for 1-5 days. Total RNA was 
extracted and reverse-transcribed to cDNA. Real-time PCR was done to determine 
the mRNA abundance of TGF β1 (Panel A), Smad2 (Panel D), Smad3 (Panel E) and 
Smad6 (Panel G). Data was normalized to 18S RNA and expressed as a ratio to the 
day 0 value. The error bars represent standard errors. Absence of an error bar denotes 
very low standard error value. *P<0.05 v.s. day 0, **P<0.01 v.s. day 0, n=3 
independent cell preparations, each assay performed in duplicates. The protein levels 
of TGF β1 (Panel B), Smad2, Smad3, Smad4, and phosphorylated Smad2 and Smad3 
(pSmad2 and pSmad3) (Panel F) were detected by Western blot using corresponding 
antibodies. GAPDH was used as the loading control. The TGF β1 secretion into the 
media during a 24 h period was determined by sandwich ELISA (Panel C). AEC II 
were cultured for 1-5 days. The medium was changed every day. At the indicated 
time points the media was collected and TGF β1 content was measured. The error 
bars represent standard errors.  
**P<0.05 v.s. day 2, ***P<0.01 v.s. day 2, n=3 independent cell preparations, each 
assay performed in duplicates. 
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TGF β1 activates its signal transduction pathway by binding to the specific TβRII-TβRI 
receptor complex on the extracellular side of the cell membrane. We therefore 
investigated whether TGF β1 was secreted from the cultured cells as they trans-
differentiated. AEC II were cultured in MDSF media, the media collected on days 2, 3, 4 
and 5  and the TGF β1 concentration was determined by sandwich ELISA. TGF β1 
secretion into the surrounding media increased significantly during trans-differentiation 
and corresponded with the increase in TGF β1 production within the cells (Fig. 3C). The 
same experiment, when repeated in MEM + 10% FBS, yielded similar results (data not 
shown).  
The mRNA expression of Smad2 and Smad3 remained lower during the proliferation 
phase and increased on day 3 as differentiation became evident (Fig. 3 D and E). This 
almost corresponded to their protein levels (Fig. 3F). Since the presence of their 
phosphorylated form would be a better indicator of the activation of the Smad-dependent 
TGF β pathway, we further determined the phosphorylation of Smad2 and Smad3 using 
antibodies that only recognized the phosphorylated form of Smad2 or Smad3. As 
expected, the phosphorylation of both Smad2 and Smad3 were increased during 
differentiation (Fig. 3F), indicative of active TGF β1 signaling. The expression level of 
Co-Smad, Smad4 protein was constant from day 0 to day 5(Fig. 3F). 
The mRNA expression levels of I-Smads, Smad6 and Smad7, were also examined. 
Smad7 mRNA level did not show significant changes (data not shown), but Smad6 
expression was higher during the proliferation phase (Fig. 3G).  
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The expression of cell cycle related proteins, p15, p21, CDK2, CDK4 and CDK6 
were altered during the trans-differentiation. 
TGF β mediates its action by altering the levels of cell cycle proteins that are involved in 
the G1 to S phase transition before the restriction point. TGF β increases the expression 
of two cyclin-dependent kinase inhibitors, p15 (Hannon and Beach, 1994) and p21 (Datto 
et al., 1995). The latter, in turn, inhibit the activity of CDK2, CDK4 and CDK6, which 
are required for the progression of the cell cycle. We examined the relative mRNA 
expression of p15 and p21 by real time PCR. Their expression remained low from day 0 
to day 3 and increased significantly as the differentiation progressed (Fig. 4 A, B). These 
results were verified at the protein level by western blot (Fig. 4C). The protein levels of 
CDK2, CDK4 and CDK6 showed an opposite trend of expression (Fig. 4C) 
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Figure 4 - The expression of cell cycle inhibitors, p15 and p21, and  CDK2, CDK4 and 






Figure 4 - The expression of cell cycle inhibitors, p15 and p21, and  CDK2, CDK4 
and CDK6 during trans-differentiation.  
A & B - RNA levels of p15 and p21:  AEC II were seeded on plastic dishes and 
cultured for 1-5 days.  Total RNA was extracted from the cultured cells collected on 
day 0, 1, 3 and 5 and reverse-transcribed to cDNA. Real-time PCR was done to 
determine the mRNA abundance of p15 (A) and p21. Data was normalized to 18S 
RNA and expressed as a ratio to the day 0 value. The error bars represent standard 
errors. Absence of an error bar denotes very low standard error value. *P<0.05 v.s 
day 0, ***P<.001 v.s. day 0, n=3 biological preparations, each assay performed in 
duplicates.  
C - p15, p21, CDK2, CDK4  and CDK6 protein levels were detected by Western 
blot using corresponding antibodies. A representative GAPDH, used as the loading 
control, is shown in the lowest panel. 
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This low expression of cell cycle inhibitors during the proliferation and their increase 
during differentiation with an opposite expression trend of CDKs further strengthen our 
view that these two phases of cell events may be mediated by the endogenous TGF β1 
released from cultured cells in this model.  
Addition of exogenous TGF β1 prior to proliferative phase blocked both 
proliferation and trans-differentiation of AEC II while its addition after the 
proliferative phase did not affect the trans-differentiation. 
The anti-proliferative effect of TGF β1 on AEC II has been documented previously 
(Zhang et al., 2004).   We investigated the effects of addition of exogenous TGF β1 prior 
to and after the proliferation phase in our trans-differentiation culture model.  For this 
purpose, AEC II were cultured for 5 days in the presence of recombinant TGF β1 at a 
concentration of 40 ng/ml from day 0 in one group (pre-proliferative addition) and from 
the end of day 2 in another group (post-proliferative addition). A control group with no 
additions was also prepared. The phenotypes of the cells on day 3 and day 5 were 
determined by double- labeling with AEC II and AEC I markers, LB 180 and P2X7, 
respectively (Fig. 5). When compared to the control (Fig. 5 panels a-c and m-o), the 
group with pre-proliferative addition of TGF β1 showed reduced proliferation and 
differentiation (Fig. 5 panels d-f and p- r). The cell counting revealed a 54% reduction in 
the cell number on day 3. The LB-180 expression in this group persisted even on day 5 
showing that they retained the lamellar bodies and AEC II phenotype. Also, the AEC I 
marker (P2X7) expression was absent in this group indicating a failure to trans-
differentiate to AEC I-like cells. A dose experiment (4, 10, 20, and 40 ng/ml) showed that 
TGF β1 as low as 4 ng/ml if added at the pre-proliferative phase can still retain AEC II 
59 
phenotype although the number of LB-180-positive cells appears to be higher at a higher 
concentration of TGF β1 (Data not shown). On the other hand, in the cells subjected to 
post-proliferative addition of TGF β1, normal trans-differentiation process was seen as in 
the untreated control with gradual loss of LB-180 expression and subsequent appearance 
of P2X7 expression (Fig. 5 panels g-I and s-u).  The results indicate that for 
differentiation to take place there must be a preceding proliferative phase. Maybe that is 
the reason why TGF β1 and related Smad expression increase after the proliferative phase 
when cells are ready for differentiation. To further clarify this view, we added an excess 
of neutralizing antibody to TGF β1 at the end of day 2 (post-proliferative addition). The 
antibody binds with the endogenous TGF β1 and makes it unavailable to bind with the 
receptors and to initiate Smad-mediated signaling. The cells retained the AEC II 
phenotype and failed to trans-differentiate properly when the endogenous TGF β1 was 
blocked. They retained the LB-180 expression and failed to express P2X7 on day 3 and 
day 5 (Fig. 5 panels j-l and v-x). These experiments demonstrate that altered signaling 
through TGF β1 is important in the trans-differentiation of AEC II to AEC I and that the 
initial proliferation phase may be essential for subsequent differentiation process. 
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Figure 5 - Effect of pre-proliferative and post-proliferative addition of exogenous TGF β1 
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and anti-TGF β1 antibody on AEC II trans-differentiation.  
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Figure 5 - Effect of pre-proliferative and post-proliferative addition of exogenous 
TGF β1 and anti-TGF β1 antibody on AEC II trans-differentiation.  
AEC II were cultured for 3 or 5 days. Recombinant TGF β1 (40 ng/ml) was added at 
day 0 (pre-proliferative addition) (panels d-f,and p-r) in one group and at the end of 
day 2 (post-proliferative addition) (panels g-I and s-u)  in another. A third group was 
post-proliferative addition of anti-TGF β1 antibody at a concentration of (40 µg/ml) 
(panels j-l and v-x). The control was without any additions (panels a-c, m-o). Cells 
were fixed on days 3 and 5 and were double-labeled with anti-LB-180 (AEC II 
marker) and anti-P2X7 (AEC I marker).  Scale bar: 7 μm.  
Silencing of Smad4 by RNAi prevented the trans-differentiation. 
Because the previous experiment involved exogenous addition of a higher quantity of 
TGF β1 which may not reflect the normal physiological conditions, we decided to block 
the Smad pathway within the cell by knocking down Smad4 expression using RNAi. 
Smad4 was chosen because it is the common partner Smad that binds with Smad2 and 
Smad3 and is an essential component of Smad-dependent TGF β signaling.  Adenovirus-
based RNAi targeted to Smad4 (AdSmad4Si) was used to silence Smad4 in AEC II. The 
viral control (AdCon) contained non-relevant siRNA sequences. AEC II were treated 
with the Adenoviruses on day 1 and Smad4 protein expression on day 3 and day 5 was 
determined using western blot. As seen in Fig. 6A, there was a significant reduction in 










Figure 6 - Effect of Smad4 silencing on trans-differentiation of AEC II to AEC I-
like cells  
A.  After 24 h of plating, AEC II were transduced with Adenoviruses 
carrying siRNAs targeted to Smad4 (AdSmad4Si) or non-relevant 
siRNAs (AdCon). The blank control was without any additions. 
Multiplicity of Infection (MOI) used was 7 for Adsmad4Si and 36 for 
AdCon. Total protein was extracted on day 3 and day 5 and Western blots 
for Smad4 were performed. GAPDH was used as the loading control.  
B. The effect of Smad4 silencing on trans-differentiation: Double labeling 
using anti-LB-180 and anti-P2X7 antibodies was done on AEC II treated 
for 5 days with AdSmad4si (panels g, h and i) and AdCon (panels d, e 
and f).  
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The consequences of silencing Smad4 on the trans-differentiation of AEC II were then 
examined by monitoring cell phenotype changes. The cells treated with AdSmad4Si 
retained the AEC II marker (LB-180) expression and failed to express the AEC I marker 
(P2X7) on day 5. The untreated and AdCon-treated cells trans-differentiated to AEC I-
like cells and showed the P2X7 expression and concurrent disappearance of LB-180 (Fig. 
6B). There was a visible difference in cell phenotypes; the AdSmad4Si-treated cells were 
rounder and smaller than the control cells. 
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DISCUSSION 
In the cells possessing the capability to proliferate and differentiate, there is substantial 
coupling between these processes. The quiescence of AEC II in normal alveoli and their 
proliferation and trans-differentiation into AEC I in injured lung illustrates how 
differential signaling through the same TGF β1 pathway might be responsible for 
controlling both processes.  
TGF β1 has been reported to be expressed in alveolar epithelial cells under pathological 
conditions. For example, TGF β1 has been observed in hypertrophic AEC II and in 
fibrotic areas immediately beneath them (Broekelmann et al., 1991; Corrin et al., 1994b; 
Khalil et al., 1996). However,  TGF β1 expression in normal AEC II has not been 
reported previously. Our immunostaining results showed that TGF β1 and its down 
stream component, Smad4 were expressed in AEC II of normal lung. These proteins were 
also detectable in AEC I although to a less extent. TGF β1 signaling may play a role in 
keeping the AEC II quiescent in normal lung.  
TGF β1 can be synthesized and secreted  by isolated AEC II. The protein level of TGF β1 
was increased as AEC II trans-differentiated to AEC I-like cells in vitro as determined by 
Western blot. The reasons for apparent low expression of TGF β1 in AEC I in the intact 
lung and its high expression in the trans-differentiated AEC I-like cells in vitro are 
unclear. However, there are several possibilities: (i) AEC I  are very thin and squamous 
cells that cover ~95% of alveolar surface while AEC II are cubodial cells that occupy 
only ~5% of the surface even though the number of type II cells is twice as many as type 
I cells in the lung.  Therefore, the signal for TGF β1 immunostaining is weak compared 
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to type II cells because of the shape of the cells; (ii) trans-differentiated AEC I in vitro 
may not reflect all the properties of the normal AEC I in vivo (Gonzalez et al., 2005). The 
changes in the cellular environment may alter its expression. 
A novel finding in the current study is the identification of a proliferation phase 
preceding the differentiation phase in the in vitro trans-differentiation cell culture model. 
The appearance of AEC I-like cells by day 3 and subsequent differentiation was 
confirmed by differential labeling using established AEC II (LB-180) and AEC I (P2X7) 
markers. The previous studies have demonstrated the presence of various AEC I markers 
in these trans-differentiated cells, indicating that they are indeed similar to AEC I (Borok 
et al., 1998b; Borok et al., 1998a; Danto et al., 1995; Dobbs et al., 1988). Although this 
differentiation pattern has been observed previously, the initial proliferation phase has not 
been reported. BrdU labeling, which is indicative of active DNA synthesis preceding cell 
division, was found to be the highest on day 2. The expression pattern of the cell cycle 
inhibitors and CDKs, reflective of the cell cycle stages substantiated this biphasic cell 
proliferation and differentiation.  
AEC I are the most susceptible to injury in alveolar epithelium. After lung injury, AEC I 
are destroyed and basement membrane denuded and AEC II proliferate and differentiate 
into AEC I to repair the epithelium (Adamson and Bowden, 1974; Evans et al., 1973; 
Narasaraju et al., 2006; Uhal, 1997). Therefore, this in vitro trans-differentiation model 
may closely relate to the process taking place in vivo during lung injury and repair. It 
should also be noted that isolating of AEC II from the lung and culturing them may 
mimic lung injury and repair. The loss of contact of AEC II with the surrounding cells 
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after isolation may initiate AEC II proliferation and then differentiate into AEC I-like 
cells.  
TGF β can be a positive or a negative regulator of cell proliferation and differentiation 
(Huang and Huang, 2005). This depends on cell type and the physiological or 
pathological stage in which the cells are. The presence of other growth factors and 
signaling cascades also determines how TGF β acts at a particular stage of growth and 
differentiation. For example, TGF ß  inhibits myogenic differentiation (Massague et al., 
1986), but promotes differentiation in mammary epithelium (Yamamoto et al., 1994). 
TGF β1 can inhibit the proliferative effects of KGF on cultured AEC II (Zhang et al., 
2004). During the recovery of hyperoxia-exposed AEC II, there is a proliferative phase 
marked by an escape from the negative autocrine regulation by TGF β3 (Buckley et al., 
1996). However, whether TGF ß has the pro-differentiation effects on AEC is unknown.  
The TGF β1, produced inside AEC, is secreted out as the trans-differentiation takes place 
and thus regulates this process in an autocrine manner. The secretion of TGF ß 1 was also 
observed in alveolar macrophages and fibroblasts from fibrotic lungs (Khalil et al., 1993; 
Venkatesan et al., 2002). An autocrine loop of TGF β1 in pregnant mouse mammary 
epithelium has been shown to aid the differentiation process (Yamamoto et al., 1994).  
When AEC II trans-differentiated into AEC I-like cells in vitro, we found that the 
changes in expression of TGF β1 and R-Smads, Smad2 and Smad3 were biphasic: lower 
in the proliferation phase and higher in the differentiation phase. The increased 
phosphorylation of Smad2 and Smad3, a hallmark of activation of the TGF β pathway, 
showed a similar trend. However, an opposite trend of expression of Smad6, an inhibitory 
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Smad was observed. The high expression of Smad6 during the proliferation phase may 
further inhibit the TGF ß signaling and ensures the initial proliferation occur before the 
differentiation. Although Smad6 is a inhibitor of BMP signaling through its binding with 
the activated Smad1 (Hata et al., 1998), overexpression of Smad6 also blocked the TGF β 
signaling (Imamura et al., 1997). The results suggest that TGF ß signaling is depressed 
during the proliferation phase and activated during the differentiation phase. 
TGF β can regulate cell cycle proteins involved in the G1 to S phase entry (Massague and 
Gomis, 2006). The activated Smad complexes caused by TGF β result in the 
transcriptional repression of the c-myc gene (Chen et al., 2001; Frederick et al., 2004; 
Pietenpol et al., 1990). Concurrent induction of two cell cycle inhibitors, p15 (Hannon 
and Beach, 1994) and p21 (Datto et al., 1995), inhibits the activity of CDK2, CDK4 and 
CDK6, which are required for the progression of the cell cycle. The expression profile of 
p15 and p21 during the trans-differentiation of AEC matched that of TGF β1 and R-
Smads. However, protein levels of CDKs 2, 4 and 6 showed an opposite trend. These 
results suggest that the coordinated TGF ß signaling through cell cyle points plays a role 
in the temporal regulation of cell cycle entry and exit by the cells. 
TGF β1, when added from day 0, stopped AEC II proliferation and later differentiation.  
The addition of TGF β1 must have aided in stopping the cell cycle during proliferative 
phase. This indicates that for differentiation to take place there must be a proliferative 
phase. This view was substantiated by the fact that the cells were refractory to the above 
stated effect of TGF β1 when it was added after the proliferative phase where normal 
differentiation ensued. Also the addition of excess of anti-TGF β1 antibody to block the 
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endogenous TGF β1 secreted caused the differentiation to stop, indicating that TGF β1 is 
essential for the differentiation process.  
The effect of exogenous TGF β1 may be quite different from that which is secreted 
during a particular stage of growth and differentiation at normal physiological levels. So 
we wanted to block the pathway within the cell. Also since Smad-independent signaling 
has been reported for TGF β1, we wanted to make sure that signaling is indeed through 
the Smad pathway. To achieve these aims, the common mediator for Smad-mediated 
TGF β signaling, Smad4, was silenced using RNAi. The results have clearly 
demonstrated a halting of the trans-differentiation process in the silenced group. 
Additionally, these results validated our view that signaling through this pathway is 
essential for the differentiation of AEC II to AEC I to occur. 
Our current studies suggest bifunctional roles of TGF β1 during the trans-differentiation 
of AEC II to AEC I: inhibit the proliferation of AEC II at the proliferative phase and 
promote their differentiation into AEC I at the differentiation phase. Once the 
proliferative phase is finished, endogenous TGF β1 induces the differentiation. This is 
supported by (i) the production of TGF β1 and the phosphorylation of Smad2/3 are 
induced at the differentiation phase; and (ii) TGF β1 antibodies if added at the end of the 
proliferative phase or silencing of Smad4 block the trans-differentiation of AEC II to 
AEC I. 
Since our model closely mimics the proliferation and trans-differentiation process that 
takes place in the lung during acute injury, understanding the signaling mechanism 
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involved in this process may help to identify the components involved as potential targets 
for rational therapeutics.   
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CHAPTER III 
MicroRNA-127 MODULATES FETAL LUNG DEVELOPMENT 
ABSTRACT 
MicroRNAs (miRNAs) are small endogenous RNAs and are widely regarded as one of 
the most important regulators of gene expression in both plants and animals. To define 
the roles of miRNAs in fetal lung development, we profiled the miRNA expression 
pattern during lung development using a miRNA microarray. We identified 21 miRNAs 
that showed significant changes in expression during lung development. These miRNAs 
were grouped into four distinct clusters based on their expression pattern. Cluster 1 
contained miRNAs whose expression increased as development progressed while clusters 
2 and 3 showed the opposite trend of expression. miRNAs in Cluster 4 including miR-127 
had the highest expression at the late stage of fetal lung development. Quantitative real-
time PCR validated the microarray results of 6 selected miRNAs. In situ hybridization 
demonstrated that miR-127 expression gradually shifted from mesenchymal cells to 
epithelial cells as development progressed. Over-expression of miR-127 in fetal lung 
organ culture significantly decreased the terminal bud count, increased terminal and 
internal bud sizes and caused unevenness in bud sizes, indicating improper development. 
These findings suggest that miR-127 may have an important role in fetal lung 
development.  
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INTRODUCTION 
MicroRNAs (miRNAs) are a class of small RNAs (~21-24 nt) that regulate the 
expression of their target genes at the post-transcriptional level (Bartel, 2004; He and 
Hannon, 2004).  In animal cells, they are first transcribed from miRNA genes in the 
genome as primary miRNAs (pri-miRNAs) and then processed by an RNase III enzyme, 
Drosha, into ~70 nt premature miRNAs (pre-miRNAs) with hairpin structures (Lee et al., 
2003).  With the help of Exportin 5, pre-miRNAs are then transported into the cytoplasm, 
where they are cleaved by another RNase III enzyme, Dicer (Lee et al., 2002; Yi et al., 
2003).  The cleavage results in double-stranded RNA duplexes. Usually, one strand of the 
duplex becomes mature miRNA (Khvorova et al., 2003).  Mature miRNAs are then 
recruited into nucleoprotein complexes called RNA-induced silencing complexes (RISC).  
Based on the pairing of miRNAs and their target sites, the complexes can negatively 
regulate the expression of their genes in three ways (Filipowicz et al., 2008). They can 
cleave the messenger RNAs. They can inhibit the translation of the messenger RNAs. 
They can accelerate deadenylation of the messenger RNAs leading to the acceleration of 
their degradation (Chen, 2004; Giraldez et al., 2006; Llave et al., 2002; Wu et al., 2006; 
Yekta et al., 2004). In rare cases, miRNAs can activate translation (Vasudevan et al., 
2007; Wu and Belasco, 2008). miRNAs are important regulatory molecules that modulate 
various biological processes including cellular physiology, developmental timing, cell 
fate determination, apoptosis, lipid and fat metabolism, insulin secretion and progression 
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of various cancers (Lodish et al., 2008; Stadler and Ruohola-Baker, 2008; Stefani and 
Slack, 2008). 
The functions of miRNAs in various aspects of lung biology are less studied, but are 
subjects of several recent investigations. Studies have suggested the important roles of 
miRNAs in lung cancer. It has been found that the decrease of let-7 expression is 
correlated to increased death rates in patients with lung cancers (Takamizawa et al., 
2004).  The expression of miRNAs in lung cancers has already been profiled. The results 
demonstrated the correlation of the miRNA expression with the prognosis of lung 
adenocarcinoma patients (Yanaihara et al., 2006). Studies on expression of important 
molecules in miRNA processing, namely members of the Argonaute (Ago) gene family, 
in the E11.5 lung have shown that Ago1 and Ago2 are enriched in branching regions, 
suggesting that miRNAs may play important roles in lung development (Lu et al., 2005). 
Inactivation of Dicer, a key component in miRNA processing, was found to cause the 
inhibition of lung epithelial branching (Harris et al., 2006). It has been reported recently 
that transgenic overexpression of the miR-17-92 cluster results in the promotion of 
proliferation and the inhibition of differentiation of epithelial progenitor cells in 
developing lungs (Lu et al., 2007). 
Rat lung development can be divided into 5 stages (Burri, 1984; Zoetis and Hurtt, 2003).  
In the first 13 days, lobar division takes place. This is called the embryonic phase.  
Following the embryonic phase is the glandular or pseudoglandular phase (13-18 days), 
in which epithelial tubes of air passages are formed but have little or no lumen.  In the 
canalicular phase (18-20 days), bronchioles are produced and a lumen can be recognized 
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in many tubules. With a further thinning of the interstitium and a flattening of the 
epithelium, alveolar ducts and air sacs are formed in the saccular phase (20 days to full 
term).  Some epithelial cells begin to synthesize and secret pulmonary surfactant. The 
final stage happens after birth and is termed the alveolar phase, in which true alveoli are 
formed. 
Each of the 5 developmental stages is coordinated by a multitude of signaling molecules 
and pathways (Weng et al., 2006).  Some of the well-studied signaling molecules include 
fibroblast growth factors, transforming growth factors (TGF), retinoids, Wnt genes and 
Sonic hedgehog (Pongracz and Stockley, 2006; Ramasamy et al., 2007; Wang et al., 
2005; White et al., 2006). However, little is known about what the role of miRNAs is in 
this process and how they regulate lung development by modulating these signaling 
pathways. In addition, the temporal and spatial expression patterns of miRNAs in rat lung 
development are still not known. 
In this study, we used a miRNA microarray platform developed in our laboratory  (Wang 
et al., 2007) to profile the expression of miRNAs at all stages in rat lung development.  
There were 21 miRNAs that were significantly changed during this process. Some of 
these miRNAs were selected and validated by real-time PCR.  The spatial expression 
patterns of selected miRNAs were determined using in situ hybridization. We  selected 
miR-127 for further study based on its expression pattern. miR-127 over-expression in an 
fetal lung organ culture at an earlier stage resulted in lesser and defective terminal bud 
formation and uneven development of the lung. These results demonstrate a critical role 
of miR-127 in fetal lung development.  
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MATERIALS AND METHODS 
Isolation of RNA from rat lung 
 Whole lungs were isolated from fetuses on gestational days 16, 19, and 21 (E16, E19, 
and E21), new born, 6-day-old, and 14-day-old (P0, P6 and P14), and 2-month-old adults 
(AD) rats.  For each time point, there were three independent biological replicates.  All 
procedures in this study followed the protocols approved by the Oklahoma State 
University Animal Care and Use committee.  For the fetal lungs, pregnant Sprague-
Dawley rats were sacrificed with CO2.  Fetuses were removed from the uterus and the 
lungs were isolated from these fetuses.  For pup and adult lungs, male Sprague-Dawley 
rats were anesthetized before sacrifice and isolation of the lungs.  Immediately after 
isolation, the lungs were rinsed with DMEM and then homogenized in the Lysis/Binding 
Buffer from the mirVanaTM miRNA Isolation Kit (Ambion, Austin, TX).  Enriched small 
RNA and total RNA from the lungs were isolated with the mirVanaTM miRNA Isolation 
Kit (Ambion) according to the manufacturer’s instructions. 
miRNA microarray 
The miRNA microarrays were performed on an in-house platform developed in our 
laboratory as described previously (Wang et al., 2007).  There are 3 identical blocks on 
each slide and 6 identical probes for each miRNA in each block. The NCode miRNA 
Labeling System (Invitrogen, Carlsbad, CA) was used to generate labeled miRNA 
molecules for hybridization to the microarrays.  Six hundred ng of RNA was used in each 
labeling reaction. One fifth of the labeled RNA was used for each hybridization.  Small 
RNAs from the lungs at certain time points were co-hybridized with the common 
reference, which was pooled equally from small RNAs of all the lung samples.  To each 
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block, one labeled samples (Alexa Fluor 3 or Alexa Fluor 5) was co-hybridized with the 
common reference labeled with the other dye (Alexa Fluor 5 or Alexa Fluor 3).  Dye 
swaps were performed to eliminate dye bias.  The hybridized slides were scanned with 
ScanArray Express (PerkinElmer Life and Analytical Sciences, Boston, MA) and the 
images were analyzed with GenePix 5.0 pro (Axon Instruments, Inc. Union City, CA).  
The data were calculated, normalized and qualified as described previously (Wang et al., 
2007).  The signal from each spot was normalized to the average signal of the whole 
block.  The highest and lowest signals from the 6 identical probes in the same block were 
excluded from further analysis.  The geometric average of the other 4 signals was 
considered to be the signal of that particular miRNA.  The qualities of the signals were 
assessed with the software, Realspot.  The miRNAs with an average QI (quality index) < 
1 were filtered.  The qualified data were then analyzed with the software SAM 
(Significant Analysis of Microarrays, Stanford University, http://www-
stat.stanford.edu/~tibs/SAM/) (multiclass response) and any miRNAs significantly 
changed between any two time points were picked up (q<0.05).  The miRNAs that passed 
the SAM test were clustered and viewed with Cluster (K means clustering) and TreeView 
software (http://rana.lbl.gov/EisenSoftware.htm). 
Quantitative Real-time PCR for miRNA 
Quantitative real-time PCR (qRT-PCR) was performed with the mirVanaTM qRT-PCR 
miRNA Detection Kit (Ambion, Austin, TX) (for miR-18, miR-20a, miR-29a and miR-
351) or TaqMan® MicroRNA Assays (Applied Biosystems, Foster City, CA) (for miR-
195 and miR-351) as per the company’s protocols. In brief, total RNA was isolated from 
rat lungs at different time points of development (E16, E19, E21, P0, P6, P14, and AD) 
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with the mirVanaTM miRNA Isolation Kit (Ambion Austin, TX). TURBO DNA-freeTM 
(Ambion) was used to remove DNA contamination. Three biological replicates were 
performed at each time point. For qRT-PCR using mirVanaTM qRT-PCR miRNA 
Detection Kit, 50 ng RNA was used in each reverse transcription reaction with miRNA 
specific mirVanaTM RT primers. Duplicate RT reactions were performed for RNA from 
each biological replicate and no template controls. The reactions were incubated in 96-
well plates at 37°C for 30 min, then at 95°C for 10 min. PCR Master Mix (15 μl) was 
added to each RT reaction. qRT-PCR was performed on an Applied Biosystems 7500 
Real-Time PCR System . The reactions were incubated at 95°C for 3 min, followed by 40 
cycles of 95°C for 15 s and 60°C for 30 s. Dissociation analysis was performed after 
amplification to identify the characteristic peak for the specific PCR product. The CT was 
determined for each miRNA.  RT and PCR for U6 snRNA were also performed in each 
plate as an endogenous control. The comparative CT method was used, and the relative 
amount of each miRNA to U6 snRNA was calculated with the equation, 2-(CT microRNA-CT 
U6). For qRT-PCR with TaqMan® MicroRNA Assays, 75 ng total RNA was used as 
template in each RT reaction with miRNA specific RT primers. The reactions were 
incubated on ice for 5 min, followed by 16°C for 30 min, 42°C for 30 min and 85°C for 5 
min.  For each PCR reaction, 1.33 μl RT product was used as a template.  The PCR 
reaction was incubated at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 
60°C for 60 s.  All PCR reactions were run in duplicate.  RT and PCR for 18 S in each 
sample were also performed as an endogenous control using TaqMan® Ribosomal RNA 
Control Reagents (Applied Biosystems). Data analysis was done as described above.   
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In situ hybridization for miRNA 
In situ hybridization for miRNA was done using 5’ DIG labeled LNA probes (Exiqon 
Woburn, MA).  Paraffin embedded rat lung tissues were dewaxed in xylene and 
rehydrated in descending grades of alcohol. The slides were then washed in PBS (pH 7.5) 
and permeablized by incubating for 10 min in proteinase-K (Ambion, Austin, TX) for 5 
min at 37oC. The slides were again washed in 0.2% glycine, fixed in 4% 
paraformaldehyde, rinsed in PBS and pre-hybridized in hybridization buffer (50% 
Formamide, 5 x SSC, 0.1% Tween 20, 9.2 mM citric acid, 50 μg/ml heparin and 500 
μg/ml yeast RNA, pH 6) in a humidified chamber. The 5’ DIG labeled LNA probes were 
then added to the sections at a 20 nM concentration and incubated overnight at the 
hybridization temperature (21°C lower than the Tm values  of the specific probes). The 
slides were rinsed in 2x SSC and washed 3 times for 30 min in 50% formamide, 2x SSC 
solution at the same hybridization temperature.  This was followed by blocking with 2% 
sheep serum, 2 mg/ml BSA in PBST (PBS + 0.1% Tween 20) and incubation with anti-
DIG-AP Fab fragments antibody (1:2000) (Roche Applied Sciences, Indianapolis, IN) 
overnight at 4°C in a humidified chamber. After washing in PBST and AP buffer (100 
mM Tris HCl, pH 9.5, 50 mM MgCl2, 100 mM NaCl and 0.1% Tween-20), the color 
reaction was carried out by incubation in the color solution, BCIP/NBT solution (Roche 
Applied Sciences, Indianapolis, IN) with 1 mM Levamisole for 6 to 24 hours at RT. The 
color reaction was stopped after observing sufficient development of blue precipitate by 
washing with PBST. The slides were then mounted, cover slipped and observed under a 
Nikon E-600 microscope.  
83 
Construction of a miR-127 overexpression adenoviral vector 
Rat miR-127 with the flanking sequences (~200 base pairs at each end) was amplified 
from rat genomic DNA using the primers: 5’-CCTTGTCGACCTCGAGAACC TCCAG-
3’ and 5’-AGAATTCTTAGGCATTAAG TGGCTCCAGACCC-3’ and digested  by Sal 
I and Eco RI digestion.  The digested PCR product was cloned into a modified 
pENTR/CMV-EGFP vector (Gou et al., 2004) between enhanced green fluorescent 
protein (EGFP) stop codon and SV40 polyA terminal sequences through Xho 1 and Eco 
R1 restriction sites.  Inclusion of CMV-driven EGFP in the vector was for the purpose of 
monitoring transfection efficiency. The empty vector of the CMV-driven EGFP was used 
as a vector control. The CMV-EGFP-miRNA in the pENTR vector was moved into an 
adenoviral vector by the Gateway technique (Invitrogen, Carlsbad, CA).  Obtained 
adenoviral vectors were linearized by Pac I and used to transfect HEK293A cells.  
Adenovirus was amplified by re-infecting HEK293A cells.  Titer of virus was determined 
by making series of dilutions of viral stock, infecting HEK293A cells and counting for 
virus infected cells and expressed as Plaque Forming Units (PFU)/ml. 
Over-expression of miR-127 in fetal lung organ culture 
E14 embryos were dissected from timed pregnant Sprague-Dawley rats.  Fetal lungs were 
isolated from each fetus by removing the surrounding tissues using 21-24 gauge needles 
and placed in Hank's buffered salt solution (HBSS). They were then cultured on 0.4 µm 
pore size culture inserts (Millipore Corporation, Billerica, MA) and placed in six well 
tissue culture plates for 2 days. Each well contained 1.5 ml  of serum-free chemically 
defined BGJb medium (Fitton-Jackson modification) (Invitrogen, Carlsbad, CA) with 0.2 
mg/ml ascorbic acid, 50 units/ml penicillin and 50 µg/ml streptomycin. The day of 
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isolation (E14) was denoted as D0 and the next 2 days of culture were denoted as D1 and 
D2, respectively. The adenoviruses containing EGFP and miRNA over-expression 
sequence or empty vector with EGFP only (Virus Control) were added to the inserts on 
D0 at a dose of 4.7 x 107 PFU/ fetal lung. As a blank control, an equal amount of DMEM 
media was added on the fetal lung. Excess liquid, if any, in the insert was removed using 
a pipette after 3 hours. Half of the initial dose of virus was added on D1 to maintain the 
over-expression as tissue mass increased.  The lung was photographed on each day using 
a digital camera mounted on to a Nikon-E 600 microscope at same magnification for 
every lung. 
Morphometric analysis of lung 
The morphometric analyses of fetal lungs were done on the images taken on D0, D1 and 
D2 at the same magnification using MetaVueTM software (Molecular Devices 
Corporation, Downingtown, PA).  The images were coded and analyses were performed 
by two blinded investigators. The number of terminal buds was counted by enlarging the 
images on the Metavue software and counting those buds which were at the periphery of 
the lung.  The number of terminal buds for each lung was divided by the number of 
terminal buds present at the time of isolation as a normalization procedure. The terminal 
and internal bud sizes were measured using the software at the longest diameter for each 
bud.  The average bud sizes were calculated by randomly selecting at least 30 internal or 
terminal buds from each lung and calculating the average for each lung.  Data was pooled 
from all the lungs that received the same treatment.  The data from at least 10 lungs 
obtained from fetuses of 3 different dams were used to measure each parameter. 
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Statistical Analysis 
Statistical analysis of microarray data was done as described earlier (Wang et al., 2007).  
One way ANOVA was performed for the real time PCR study pertaining to miR-127 
over-expression in fetal lungs, followed by the Dunnett’s multiple comparison test for 
comparison between individual treatments.  For all other studies, a paired t-test was done 
between the virus control and miR-127 over-expression group.  A p value of < 0.05 was 
considered significant.  All values are presented as means ± S.E. 
RESULTS 
miRNA expression profile during lung development.  
To detect the miRNA expression profile during rat lung development, we used the 
miRNA microarray platform developed in our laboratory (Wang et al., 2007).  The 
microarray contained probes for 227 non-redundant RNAs: 177 rat miRNAs, 5 human 
miRNAs, 31 mouse miRNAs and 14 other kinds of RNAs and controls.  Small RNAs of 
rat lungs from 7 time points of lung development (E16, E19, E21, P0, P6, P14, and AD) 
were co-hybridized onto the slides with the common reference, which consisted of equal 
amounts of enriched small RNAs from each time point. Three biological replicates and 
dye swaps were performed for each sample. 107 miRNAs passed the quality test by 
RealSpot with an average QI>1 (Chen and Liu, 2005). The statistical analysis was 
performed with SAM.  21 miRNAs were shown to have significant changes between at 
least one pair of the 7 time points (q<0.05). These significantly changed miRNAs were 
then grouped into 4 clusters with Cluster software by K-means clustering (Fig. 7)  
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The first cluster included let-7b, miR-29a, 
miR-23a, miR-22 and miR-195. The second 
one included miR-298, miR-341, miR-130b 
and miR-92.  The third one included miR-
17, miR-214, miR-106b, miR-93, miR-290, 
miR-20a, miR-17-5p and miR-18. The last 
one consisted of miR-127, miR-210, miR-
19b and miR-351.  
Figure 7 - Cluster analysis of miRNAs  
Cluster analysis of miRNAs significantly 
changed during rat lung development. 
miRNAs from lungs on gestational days 
16, 19 and 21 (E16, E19 and E21), 
postnatal days 0, 6 and 14 (P0, P6 and 
P14, or adult lungs (AD) were co-
hybridized with the common reference. 
The normalized data were subjected to 
SAM test to identify miRNAs whose 
expression were significantly changed 
during this process (q<0.05). The 
identified miRNAs were grouped into 4 
clusters by K-mean clustering and viewed 
by TreeView. Each column represents one 
stage and each row represents one 
miRNA. Each value of expression is the 
average of 6 replicates and is then log2 
transformed. Red represents positive 
values, green negative values, and black  
zero. 
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The expression patterns of the identified miRNAs are shown in the line charts (Fig. 8).  In 
the first cluster, the miRNA expression  increased gradually from fetal to adult lungs 
(E16 to AD). The miRNAs in the second and third cluster decreased from E16 to AD, a 
large part of which markedly decreased from E16 to E19. In the fourth cluster, all the 
miRNAs peaked at some point between E16 and P6. For example, miR-127 reached 
maximum on E21 and miR-351 reached maximum on E19.  
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Figure 8 - miRNA expression patterns during rat lung development 
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Figure 8 - miRNA expression patterns during rat lung development 
The relative expression of miRNAs in each cluster of Fig. 7 is plotted 
against each stage of development. The relative expression level is the 
ratio of the sample signal to the common reference signal. The data 
shown are the means of 6 replicates. 
Real-time PCR validation of the microarray results 
We wanted to validate our microarray results using a more sensitive and quantitative 
method. qRT-PCR was done to confirm the trends of expression exhibited by miRNAs 
from each of the 3 clusters. miR-29a and miR-195 (Fig. 9a and b) were chosen to 
represent the 1st cluster, while miR-18 and miR-20a (Fig. 9c and d) represented the 3rd 
cluster and miR-127 and miR-351 (Fig. 9e and f) represented the 4th cluster.  All of these 
miRNAs followed the same trend of expression as seen in the microarray experiment, 
thus validating our microarray platform.  
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Figure 9 - Validation of miRNA microarray results using quantitative real-time PCR 
 
91 
Figure 9 - Validation of miRNA microarray results using 
quantitative real-time PCR  
Total RNA was extracted from the fetal lungs with gestational 
days 16, 19 and 21 (E16, E19 and E21) and the lungs of postnatal 
days 0, 6, 14 and adult (P0, P6, P14 and AD). miRNA levels were 
measured by real-time PCR. The relative expression levels of 
miR-29a, miR-195, miR-18, miR-20a, miR-127 and miR-351 were 
expressed as percentages of maximum expression. The error bars 
represent standard errors. n=3 independent preparations, each 
assay performed in duplicates. The microarray data shown are 
averages from 6 replicates.  
Cellular localization of miRNAs 
In situ hybridization using 5’ DIG labeled LNA probes was done to determine the spatial 
expression pattern of selected miRNAs in tissue sections from different stages of lung 
development. A U6 probe was used as a positive control. Positive signals were observed 
in nuclei of all the cells on P0 sections (Fig. 10a P0-Pos). miR-20a expression followed 
the trend of expression consistent with the microarray and qRT-PCR data (Fig. 10a). 
Expression was seen on E16 and not in other stages of development. The signal on E16 
was confined mainly to cells of mesenchymal origin in the interstitium. A probe that 
contained a scrambled sequence and had no known miRNA targets was used as a 
negative control.  No signals were detected on E16 sections (Fig. 10a, E16-Neg).  The 
miR-127 expression pattern also followed the trend of expression as seen in the qRT-PCR 
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and microarray experiments (Fig. 10b). It was highest at E19, E21 and P0 stages.  E19 
sections showed miR-127 expression both in epithelial and mesenchymal cells, but more 
in mesenchymal cells. In E21 sections, the expression shifted more towards the epithelial 
regions lining the airways.  P0 lungs showed much weaker signal intensity than E21 but 
the trend of expression was the same as on E21. Adult lung sections did not give any 
signals for miR-127. There was no signal from the lining of blood vessels (data not 
shown). The miR-351 expression pattern also corroborated the qRT-PCR and microarray 
data (Fig. 10c). E16 sections showed miR-351 expression both in epithelial and 
mesenchymal cells, but more in epithelial cells lining the future terminal airways and 
alveoli.  Expression was highest in E19 stage where miR-351 was seen both in epithelial 
cells and mesenchymal cells. The expression was strongest in the epithelial cells lining 
the terminal bronchioles (Fig. 10c, inbox) while it was absent in the lining of blood 
vessels.  E21 showed the same pattern of expression though much weaker than E19.  
Also, the expression shifted more towards epithelial cells lining the alveoli than in 
mesenchymal cells. The weakening of the signal continued to the P0 stage and signal was 
seen mainly in epithelial cells lining the alveoli and terminal air spaces.  In adult tissue 
section, the signal was exclusive and specific in alveolar type II cells and could not be 
detected in other cells.  In all stages, no signal was detected from the lining of blood 
vessels (data not shown). 
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Effect of miR 
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Figure 10b - In situ hybridization for miR-127 
 
127 over-expression on fetal lung development 
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Figure 10c - In situ hybridization for miR-351 
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Figure 10 - In situ hybridization for  miRNAs 
In situ hybridization was carried out in dewaxed and rehydrated fetal rat lung 
tissue sections from gestational days 16, 19 and 21 (E16, E19 and E21) and the 
lungs of postnatal day 0 and adult (P0 and AD). The sections were hybridized 
with 5’ DIG labeled LNA probes against miR-20 (a), miR-127 (b) and miR-351 
(c). A probe with scrambled sequence unrelated to known miRNAs was used 
as a negative control (Neg) and a probe for U6 was used as a positive control 
(Pos). Positive signals were visualized as dark blue/purple color. Arrow heads 
denote signals from epithelial cells while the arrows denote signals from 
mesenchymal cells. Scale bar: 40 µm.  
Effect of miR-127 over-expression on fetal lung development.  
 miR-127 was selected for further functional studies because of its interesting expression 
trend. miR-127 was expressed at E19, E21 and P0, the period immediately before birth 
and the period directly after birth.  We decided to over-express miR-127 at an earlier 
stage of development (E14) in an in vitro fetal lung culture model to see whether it causes 
any changes of fetal lung development. An adenoviral vector that over-expressed miR-
127 was used to transduce E14 fetal lungs cultured for 2 days as described in Materials 
and Methods. miR-127 over-expression and its effect on lung branching morphogenesis 
were visualized on each day (Fig. 11a). The dose of the virus was standardized by 
examining the intensities and even distribution of GFP along the whole lung. Since there 
was a significant increase in the lung tissue mass as a function of culture time, we added 
half the initial dose of virus on D1 and this gave a constant and more even GFP 
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expression than a single treatment on D0. The same treatment regimen was followed for 
both virus control and blank control. The over-expression was confirmed using real-time 
PCR (Fig. 11b). It was seen that there was a significant increase in miR-127 over-
expression on D1 and D2. An increase in the endogenous expression of miR-127 was also 
noted as the culture progressed. 
Figure 11 - miR-127 over-expression in fetal lung culture 
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Figure 11 - miR-127 over-expression in fetal lung culture 
(a) E14 fetal lungs were cultured in an insert. miR-127 over-expression adenovirus 
or virus control (VC) were added to the culture on day 0 (D0) and culture continued 
for 2 days (D1 and D2). The blank control (BC) was treated with medium alone. The 
images and GFP fluorescence were taken at D0-D2. Each treatment was carried out 
in at least 10 lungs from 3 different mothers in 3 separate experiments.  
(b) qRT-PCR to quantify the over-expression of miR-127. Total RNAs from D1 and 
D2 of the fetal lung culture were isolated. miR-127 levels were measured by qRT-
PCR. The error bars represent standard error. n=3 independent preparations, each 
assay performed in duplicates.  *P<0.05 v.s. VC, **P<0.02 v.s. VC. 
miR-127 over-expression resulted in a larger terminal bud size when compared to blank 
control (BC) and virus control (VC) (Fig. 12a and b).  Variability in the sizes of terminal 
buds was also plotted on a graph by arranging the various terminal bud sizes from at least 
250 terminal buds from 10 fetal lungs per treatment in ascending order of their individual 
sizes. The sizes of the terminal buds from the lungs treated with miR-127 seemed to 
fluctuate unevenly between almost 10 to 180 relative units while those treated with virus 
control or  blank control showed a size variation that fluctuated in a much narrower range 
(20-80 relative units) (Fig 12 C). The average internal bud size was higher for miR-127 as 
in the case of terminal buds when compared to controls (Fig. 12d). We define internal 
buds as those buds which were not at the periphery of the developing lung. They were 
enclosed and not tubular and budded out from the secondary tubular formations in the 
developing lung.  The terminal bud count, another important indicator of proper lung 
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branching, showed that miR-127 over-expression decreased the number of terminal buds. 
Fig 12e)  Taken together, miR-127 over-expression resulted in larger yet lesser numbers 
of terminal buds which showed a high amount of variability between bud sizes and this 
trend was reflected in internal buds too.  These results clearly demonstrate that miR-127 
if over-expressed at an early stage causes defective lung branching morphogenesis.  
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Figure 12 - Effect of miR-127 over-expression on fetal lung development.    
E14 fetal lungs cultured in inserts were treated with miR-127 over-expression 
adenovirus or viral control (VC) or blank control (BC) for 2 days. Images were 
taken at the end of culture. (a) An enlarged image from Fig. 5a. (b) Terminal bud 
width was measured using Metavue software. The width of each bud was 
measured at its longest diameter and expressed in relative units (c) Variability in 
the terminal bud width. The terminal bud width values were arranged in 
ascending order in each treatment and plotted against the number of buds to 
demonstrate the variability in the terminal bud size.  The data was obtained from 
more than 250 terminal buds from at least 10 fetuses obtained from 3 mothers. (d) 
Average internal bud width was calculated using metavue software and the same 
measuring parameter for terminal buds. The value was expressed in relative units.  
(e) The number of terminal buds formed at the end of day 2 in miR-127 over-
expressed lungs was compared with VC and BC after normalizing with the 
terminal buds on day 0. The number of terminal buds was counted blindly by at 
least 2 different individuals and the relative number at the end of day 2 was 
expressed as a ratio to number of terminal buds on day 0. At least 25 terminal or 
random internal buds from each lung were used for the respective analyses. The 
data is from at least 10 lungs obtained from 3 different mothers (n=3). The error 
bars represent standard error. *P<0.05 v.s. VC, **P<0.02 v.s. VC.  
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Target Prediction of Identified miRNAs  
The target genes of the identified miRNAs were predicted by TargetScan  
(http://genes.mit.edu /targetscan.test/ucsc.html) and PicTar (http://pictar.bio.nyu.edu/).  
Gene ontology (GO) information (http://www.geneontology.org/) on gene functions 
revealed 24% and 18% of the target genes are related to cell growth/maintenance and 
signal transduction, respectively. Assuming that up- or down-regulation of miRNAs 
results in down- or up-regulation of their target genes, we further used GenMAPP 
(www.genmapp.org) and KEGG Pathway database (http://www.genome. ad.jp/kegg/ 
pathway.html) to identify biological pathways regulated by miRNAs. Two major 
pathways that are potentially involved in lung development, TGF-β and Wnt/β-catenin 
pathways, were identified. Sixty five components in the TGF-β pathway were targeted by  
the miRNAs on our array (KEGG); of them, 37 were targeted by the 21 miRNAs changed 
during lung development. The numbers of the components in the TGF-β pathway 
targeted by each cluster are also listed in Table 2. 
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Table 2  miRNAs targeting different pathways 
 
Similar analysis was done with the Wnt/β-catenin pathway. 40 components in the Wnt/β-
catenin pathway were targeted by the identified 21 miRNAs. Further studies on the 
regulation of these pathways by these miRNAs will help to uncover the functions of 
miRNAs in lung development. 
DISCUSSION 
In the present work, we described the miRNA expression profile during lung 
development and identified four clusters of miRNAs that showed specific trends of 
expression.  Expression levels of 21 miRNAs were found to be significantly changed 
during the course of lung development. The miRNA microarray results were validated by 
qRT-PCR analysis and in situ hybridization of the selected miRNAs. The over-expression 
of miR-127 in a fetal lung organ culture system caused defective lung development 
characterized by decreased terminal bud counts and varied bud sizes.  
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miRNAs have rapidly emerged as one of the key regulatory molecules that control 
various biological processes ranging from development to disease.  Various miRNAs 
have been implicated in regulating developmental timing and controlling left/right 
neuronal asymmetry in Caenorhabditis elagans (Johnston and Hobert, 2003; Reinhart et 
al., 2000), insulin secretion (Poy et al., 2004), lipid metabolism (Esau et al., 2006), 
modulating proliferation and apoptosis  (Brennecke et al., 2003; Cheng et al., 2005), stem 
cell division (Hatfield et al., 2005; Shcherbata et al., 2006) and B cell differentiation 
(Xiao et al., 2007). Involvement of miRNAs in progression of various cancers have been 
extensively investigated (Blenkiron et al., 2007; He et al., 2005; Ma et al., 2007; 
Subramanian et al., 2007; Takamizawa et al., 2004; Yanaihara et al., 2006).  But studies 
on their role in the  physiology of the lung have been very limited. Some important 
proteins involved in miRNA processing such as Ago1, Ago2, and Dicer have been shown 
to be important to lung morphogenesis (Harris et al., 2006; Lu et al., 2005).  These 
discoveries suggest the importance of miRNAs in the lung.  Our previous study has 
shown that two miRNAs, namely, miR-195 and miR-200c, are specifically expressed in 
the lung (Wang et al., 2007).  It has been shown that the expression levels of some 
miRNAs are changed after lipopolysaccharide-induced inflammation and miR-146a can 
regulate the inflammatory response in lung alveolar epithelial cells (Moschos et al., 2007; 
Perry et al., 2008).   
The first cluster we identified included miR-29a and miR-195. Their expression remained 
low during all stages of fetal lung development and was  high in adult lung. miR-29a 
showed a similar trend of expression during development of the brain, i.e. low in 
embryonic brain tissue and high in adult cortex and striatum (Landgraf et al., 2007). 
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Over-expression of the miR-29 family in lung cancer cell lines has been shown to inhibit 
tumorigenicity both in vitro and in vivo (Fabbri et al., 2007).  miR-195, on the other hand, 
has been identified as a key regulator of cardiac growth and function. The over-
expression of miR-195 in cardiomyocytes led to abnormal cardiac remodeling and heart 
failure (van Rooij et al., 2006).  Its low expression during lung development may be an 
important factor that helps in the controlled proliferation and differentiation of cells in the 
lung.  This cluster also contained let-7b, a member of let-7 family known to regulate 
developmental timing in drosophila (Pasquinelli et al., 2000). 
The second and third clusters contained miRNAs whose expression decreased as the 
development progressed.  Interestingly, this cluster contained miR-17-5p, miR-18 and 
miR-20a, all of which are encoded by the miR-17-92 cluster, a conserved gene that 
encodes 7 miRNAs. A recent study in mouse embryonic lung development has shown a 
similar trend of expression for these 3 miRNAs from E11.5 to adult lungs (Lu et al., 
2007). Our In situ hybridization of miR-20a indicated its expression in the mesenchymal 
region only at E16. The expression rapidly disappeared as the development progressed. 
Analysis of predicted targets of miR-17-92 cluster showed that almost 58% of their 
predicted targets were transcription factors, regulators of nucleotide or nucleic acid 
metabolism or cellular protein metabolism, all of which are key features in driving the 
developmental process in the right direction.  
The miR-17-92 cluster has been found to be over-expressed in lung cancers and has been 
demonstrated to promote proliferation and inhibit differentiation of lung epithelial 
progenitor cells (Hayashita et al., 2005; Lu et al., 2008; Lu et al., 2007; Matsubara et al., 
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2007). This cluster has also been demonstrated to influence the translation of E2F family 
of transcription factors which are important in regulation of cell cycle and apoptosis 
(O'Donnell et al., 2005). A recent study has shown that miR-20a has an important role in 
the regulation of E2F2 and E2F3 expression (Sylvestre et al., 2007). The same study 
found that E2F1, E2F2 and E2F3 could directly bind to the promoter of miR-17-92 
cluster and act as an auto regulatory feed loop mechanism. miR-20a, also seemed to have 
an anti-apoptotic role in this study where its over expression decreased apoptosis in a 
prostrate cancer cell line and its inhibition caused increased cell death. Another group 
found that E2F3 was the primary E2F family member that bound to the promoter of miR-
17-92. They have proposed that the miR-17-92 is also pro-proliferative as it shifts the 
transcriptional balance towards the proliferative E2F3 network than the pro-apoptotic 
E2F1 network (Woods et al., 2007). The anti-apoptotic role of miR-20a and miR-17-5p 
was further confirmed in another study where their inhibition caused increased apoptosis 
in lung cancer cells (Matsubara et al., 2007). These studies have concentrated on the 
effect of miRNAs on cancer cell lines.  Their role in affecting the expression of E2F 
factors in normal cells of a developing organ have not been studied.  Since controlled cell 
death, proliferation and differentiation go hand in hand in the development of any organ 
systems and since these miRNAs seem to regulate these processes, we believe that they 
have a critical role in regulating lung development as well. This view is strengthened by 
another study where the members of miR-17-92 family have also been implicated in the 
promotion of adipocyte differentiation by negatively regulating Rb2/p130, the 
retinoblastoma genes which also interact with E2F transcription factors (Wang et al., 
2008). 
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The fourth cluster contained miR-127 and miR-351, which showed the highest expression 
just before and after birth in the sacculo-alveolar stage. Many dramatic events including 
differentiation of alveolar epithelial type I and type II cells, the initiation of formation of 
alveoli and progressive decrease in the interstitial tissue occur in these stages (Burri, 
1984; Roth-Kleiner and Post, 2005). 
 In situ hybridization showed that both miR-127 and miR-351 tend to shift from the 
mesenchymal compartment of the developing lung to the epithelial cells, which may 
indicate a role for these miRNAs in the cellular re-organization process and 
differentiation of alveolar  epithelial cells or mesenchymal to epithelial transition.   
miR-127 is embedded in a CpG island and remains methylated in most tissues except 
sperm. It shows an imprinted expression in the mouse (Seitz et al., 2004; Seitz et al., 
2003). The functional studies on miR-127 so far has identified it as a potential tumor 
suppressor whose expression goes down in cancer cell lines and in a significant number 
of primary tumors (Saito et al., 2006).  When treated with chromatin modifying drugs, 
miR-127 expression was up-regulated, and this, in turn, inhibited the expression of its 
target, a protooncogene, BCL6. Modulation in the miR-127 expression pattern in the 
context of organ development has not yet been reported. The over-expression of miR-127 
in E14 fetal lung cultures significantly affected the normal branching and terminal bud 
formation, indicating its role in fetal lung development. 
Taken together, our results have demonstrated the reliability  of a miRNA microarray 
platform to identify the miRNA profile during fetal lung development. We have also 
confirmed the expression profile and localization of selected miRNAs and have 
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demonstrated that miR-127 over-expression results in defective fetal lung development. 
Since miRNAs are believed to have multiple targets and because there are many 
signaling pathways that are involved in the lung development process, it is likely that the 
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CHAPTER IV 
MicroRNA EXPRESSION PROFILE IN BRONCHOPULMONARY DYSPLASIA 
ABSTRACT 
MicroRNAs (miRNAs) are small RNAs ~21-24 nucleotides in length. They are 
endogenous in origin and regulate the expression of proteins post transcriptionally. 
miRNA expression profile in a disease provides valuable insights into the pathogenesis of 
that disease and possible therapeutic strategies. Bronchopulmonary dysplasia (BPD) is a 
chronic lung disease manifested in premature infants and has multifactorial etiology. 
BPD can be attributed to the dysregulation of normal lung development due to defects in 
signaling and regulatory components involved. In this study we determined the miRNA 
profile in BPD using miRNA microarray. In a rat model that exhibited the pathology for 
‘new’ BPD, we found that five miRNAs, miR-342, miR-335, miR-150, miR-126* and 
miR-151* were downregulated and three miRNAs miR-21, miR-141 and miR-34a 
upregulated in the diseased lungs. The expression of these miRNAs was confirmed using 
quantitative real-time PCR and their possible functional significance have been 
discussed. Identification of miRNAs involved is the first step towards deciphering the 
fine control mechanisms involved in the spatial and temporal regulation of proteins that 
contribute to the pathogenesis of BPD. 
Keywords: Bronchopulmonary dysplasia, microRNA, Preterm infants, new BPD 
pathology, miRNA microarray.  
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INTRODUCTION 
Spatially and temporally controlled cascades of signaling through multiple pathways and 
transcription factors are important in the normal development of any organ systems. The 
dysregulation of one or more of these factors contribute to the pathogenesis of various 
diseases. The recent discovery of small non-coding RNAs called microRNAs (miRNAs) 
has added a new dimension into regulatory mechanisms that control development and 
disease. These ~21-24 nucleotide long RNAs can inhibit protein expression at 
translational level (Lee et al., 1993; Bartel, 2004). They exert their regulatory control 
over signaling cascades that govern multiple biological processes in a wide array of 
organisms (Pasquinelli et al., 2000; Mattick, 2003). The regulation/dysregulation of 
multiple proteins by microRNAs and thereby the pathways involved might be a 
contributing factor to the pathogenesis of various diseases. 
miRNAs are transcribed as primary miRNAs (pri-miRNAs) which are hundreds of 
nucleotides long. An RNase III enzyme called drosha within the nucleus processes the 
pri-miRNA into ~70 nucleotide precursor miRNA (pre-miRNA)(Lee et al., 2003). The 
pre-miRNA has a stem-loop structure and has a typical 5’ phosphate and ~2 nucleotide 
overhang. A Ran-dependent nuclear transport protein named exportin-5 (Exp5) mediates 
the transport of pre-miRNA into the cytoplasm (Yi et al., 2003; Lund et al., 2004). 
Another RNase III enzyme, dicer, processes pre-miRNAs to mature ~21-24 nucleotide 
duplexes (Lee et al., 2003; Yi et al., 2003). The mature miRNAs are recruited into 
nucleoprotein complexes called RNA- induced silencing complexes (RISC) (Schwarz et 
al., 2003). The mechanism by which these complexes regulate the expression of the 
target protein may vary depending upon the complementarity between the miRNA and 
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target regions on the mRNA. A higher complementarity is believed to degrade the mRNA 
(common in plants) and lower complementarity leads to translational suppression 
(common in animals) (Hutvagner & Zamore, 2002). Another mechanism of action has 
been recently proposed where miRNA binding leads to faster deadenylation and thereby 
degradation of target mRNA (Wu et al., 2006).  
Bronchopulmonary dysplasia (BPD) is the chronic lung disease of infancy. Multiple 
factors contribute to the manifestation of this disease. Immaturity of lung due to pre-term 
birth, complications due to positive pressure ventilation and a high concentration of 
oxygen leading to oxidant injury, barotraumas, volutrauma and treatment using pro-
inflammatory mediators are considered to be major contributing factors to this disease 
(Northway et al., 1967; Groneck & Speer, 1995; Van Marter et al., 2000; Jobe & 
Ikegami, 2001; Turunen et al., 2006). New treatment strategies like exogenous surfactant 
administration and advances in critical care management of premature babies have 
changed the course of disease progression and related pathology (Coalson, 2003). The 
‘old’ BPD pathology manifest due to high concentration of oxygen and ventilator induced 
injury on an immature and surfactant deficient lung (Coalson, 2003, 2006). The lesions 
included fibrosis, cellular hyperplasia, vascular lesions and various degrees of air way 
injury and inflammation (Bonikos et al., 1976; Kunig et al., 2005). The ‘new’ BPD 
pathology is less severe and manifests as a result of an immature lung forced to undergo 
gaseous exchange without completing the proper development process. The pathology, 
here, is characterized by decreased fibrosis, large and simplified alveoli, capillary defects, 
negligible airway epithelial lesions, variable interstitial fibro proliferation and smooth 
muscle hyperplasia (Husain et al., 1998; Coalson, 2003). Alveolar simplification and 
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enlargement of alveoli are the major and consistent changes in ‘new’ BPD pathology. 
Insight into the developmental process of the lung, especially interdependence of 
alveolarization and microvascular development, may be paramount in understanding the 
pathophysiology of BPD (Jobe & Bancalari, 2001). The expression profile and role of 
individual miRNAs in the development of various diseases are subjects of many current 
investigations. They have already been implicated in the pathogenesis of various diseases 
like cancer (He et al., 2005a; Yanaihara et al., 2006; Blenkiron & Miska, 2007). miRNA 
expression have also been demonstrated to be very important in regulating the physiology 
of development of various tissues, cell types and metabolic processes (Brennecke et al., 
2003; Cheng et al., 2005; Esau et al., 2006; van Rooij et al., 2007; Zhao et al., 2007).  In 
the lung, dicer knockout has already been shown to impair lung development implicating 
the role of miRNA in controlling lung morphogenesis (Lu et al., 2005; Harris et al., 
2006). Another study have shown that miR-17-92 cluster might be important in the 
differentiation of epithelial progenitor cells in developing lung (Lu et al., 2007) 
In this study, we have profiled miRNAs in BPD on a microarray platform. We found five 
miRNAs that were significantly downregulated and 4 miRNAs that were upregulated in 
BPD. The expression profile of eight of these miRNAs was confirmed using quantitative 
real time PCR. This would give us insight into the target proteins whose expression 
changes might be important in the pathogenesis of this disease and possibly, new tools 
for rational therapy. 
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MATERIALS AND METHODS 
Animals, treatment and sample collection 
All animal procedures were carried out according to the protocol approved by the Animal 
Care and use Committee at Oklahoma State University.  Timed pregnant Sprague-
Dawley rats were bred in house. Only pups from two mother rats which gave birth within 
0-3 hour interval were used in each set of experiment so as to ensure the same stage of 
development. The pups from each litter were marked and then divided equally one day 
after birth (P1, P0 being the day of birth). Half of the pups from one mother were mixed 
with half of the litter of another. Each of these mixed pup group was assigned to the two 
mothers. The mothers were then switched between litters each day so that they were 
trained to feed foster pups. From P3, one mother with the mixed litter was exposed to 
~95% oxygen in a sealed plexi-glass chamber (90 x 45 x 45 cm). Thereafter the mothers 
were interchanged every 24 hours till P13. The time points and oxygen concentration 
were selected as per previously reported studies where the structural changes resembled 
the ‘new’ BPD pathology (Veness-Meehan et al., 2000; Veness-Meehan et al., 2002) The 
oxygen concentration was continuously measured using an oxygen sensor (Vacu-Med, 
Ventura, CA). The oxygen flow rate was maintained at 4 liters/min and the chamber was 
cleaned everyday. Soda lime was used to remove excess CO2. On P14, the animals were 
anesthetized, and midline sternotomy was performed on each animal to expose and 
remove lung for further studies.   
Sample collection 
RNA: A total of 8 lung samples were used for this purpose, 4 BPD lung and 4 normal 
control lungs. It was made sure that each of the 4 lung per treatment came from pups born 
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to 4 separate mothers.  The lungs were washed in DMEM and homogenized in the 
Lysis/Biniding Buffer from mirVanatm miRNA isolation kit (Ambion, Austin, TX). Total 
RNA and enriched small RNA was isolated using mirVanatm miRNA isolation kit 
(Ambion) according to the manufacturer’s instructions. 
Fixation of lung tissue and sectioning: After midline sternotomy, lungs were perfused 
with ice cold PBS through right ventricle. The trachea was cannulated, and 4% 
paraformaldehyde was instilled into the lung under constant pressure (30 cm H2O for 25 
minutes). The inflation pressure was chosen based on previous studies (Hayatdavoudi et 
al., 1980; Bachofen et al., 1982). The trachea was then ligated at this constant distending 
pressure and lungs were removed and immersed in 4% paraformaldehyde for 24 hours. 
Paraffin embedded sections of 4 µm thickness on glass slides were made for further 
morphometric analysis and staining. 
Histological staining and morphometric analysis 
Morphometric analysis was performed on hematoxylin and eosin stained slides (Ashour 
et al., 2006). Two parameters were measured to quantify interalveolar distance. One was 
mean alveolar diameter (MAD) where the longest distance between walls of single 
alveoli was measured using MetaVue software (Molecular devices, Sunnyvale, CA). At 
least 20 alveoli / field were measured and at least 8 fields were counted per lung section 
and expressed in relative units. The other was mean alveolar intercept (MLI) 
measurement. The measurement was done as described by other group (Ashour et al., 
2006) with some modifications. Briefly, the H & E stained sections of both BPD and 
control lung were used to capture images using a mounted digital camera under 10 X 
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objective of a Nicon Eclipse E600 microscope. Similar fields were selected which were 
devoid of many bronchi and bigger blood vessels. Using the MetaVue software, the 
digital images where enhanced to the same magnification and five lines were drawn 
across each image: two connecting opposite vertices, 2 bisecting the opposite sides and 
one at a random position. The MLI was then calculated by dividing the length of each 
line by the total number of alveolar intercepts for that line. Twenty five lines were used 
per lung to calculate the MLI and there were at least 4 lungs per treatment. 
For alveolar secondary crests analysis, modified Hart’s elastin staining was done. The 
resorcin-fuchsin stock solution, tartarazine and the protocol were generous gifts from Dr. 
Barry Starcher at University of Texas Health Center at Irving. Briefly, the slides were de-
paraffinized in xylene and rehydrated in descending grades of alcohol. They were then 
placed in the working solution made by diluting the resorcin-fuchsin stock  using 70% 
alcohol and concHCl. The staining was done overnight. Counter staining was done using 
tartarazine solution made using water and acetic acid. Elastin was stained purple to black 
and tartarazine provided a yellow background. For quantification, the number of alveolar 
secondary crests per 20 X field was counted and at least 5 such fields were counted per 
slide. There were 4 lungs per treatment. 
Microarray 
miRNA expression profiling was performed on an in-house miRNA microarray platform 
as previously described (Wang et al., 2007). For each sample, 600 ng enriched small 
RNA was labeled with the NCode miRNA Labeling System (Invitrogen, Carlsbad, CA) 
and purified with the MinElute PCR Purification Kit (Qiagen, Valencia, CA). Labeled 
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RNA recovered from 120 ng small RNA was used in each hybridization. Equal amounts 
of small RNAs of all the samples were pooled together as a common reference. To each 
block, one sample labeled with Alexa Fluor 3 or Alexa Fluor 5 was co-hybridized with 
the common reference labeled with the other dye (Alexa Fluor 5 or Alexa Fluor 3). Dye 
swaps were performed. After hybridization, the slides were scanned with ScanArray 
Express (PerkinElmer Life and Analytical Sciences, Boston, MA) and the images were 
analyzed with GenePix 5.0 pro (Axon Instruments, Inc. Union City, CA). The signals 
were qualified with the software, Realspot (Chen & Liu, 2005). MiRNAs with an average 
QI (quality index) < 1 were excluded from further analysis. The miRNAs that passed the 
quality test were then analyzed with the software SAM (Significant Analysis of 
Microarrays, Stanford University, http://www-stat.stanford.edu/~tibs/SAM/). 
Quantitative real time PCR 
The qrtPCR was performed following the protocol described previously with some 
modifications (Shi & Chiang, 2005). Total RNA was treated with TURBO DNA-freeTM 
(Ambion) to remove DNA contamination. The Poly(A) tail was added to total RNA (1 
μg) by E. coli Poly(A) Polymerase (Ambion) at 37°C for 1 h. The first strand cDNA was 
generated with M-MLV Reverse Transcriptase (Invitrogen) and Poly T adaptor (5’-
GCGAGCACAGAAT TAATACGACTCACTATAGGTTTTTTTTTTTTVN-3’, where 
V= A, G or C, N= A, T, G or C). The first strand cDNA was diluted 50 times. The diluted 
template cDNA (10 μl) was mixed with 12.5 µl qPCRTM Mastermix Plus for SYBR® 
Green I – Low Rox (Eurogentec, San Digeo, CA), the universal reverse primer and the 
forward primer specific for each miRNA to a  final volume of 25 µl. The list of primers is 
given in Table 1. The reactions were incubated at 95°C for 10 min, followed by 40 cycles 
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of 95°C for 15 s and 60°C for 60 s. All PCR reactions were carried out in duplicate. U2 
was also amplified as an internal reference. The relative expression of each miRNA was 
calculated with the equation, 2-(CTmiRNA-CTU2) 












Reverse primer 5’-GCGAGCACAGAATTAATACGAC-3’  
 
Statistical Analysis 
For microarray, statistical analysis was done as described earlier. For all other 
experiments, paired t-test was performed. A p value of < 0.05 was considered significant.  
All values are presented as means ± S.E. 
RESULTS 
Survival, lung histology, morphometrical analysis, fibrin deposition and alveolar 
secondary crest formation 
In both oxygen-exposed and control pups, the survival rate was similar (100%) till P7. 
From P7 mortality was observed in the oxygen-exposed group. By the end of treatment 
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(P13) the survival rate of the exposed group was 44% while that of control was 100%. 
This is consistent with the previously reported survival rates in hyperoxia exposure 
studies in neonatal rats (Wagenaar et al., 2004). 
From H&E stained sections, microscopic lesions in the lung specimens are consistently 
present in tissues from treated (BPD) animals and ranged from moderate to marked in 
severity (Fig.13a).  In lungs from animals with BPD, alveolar septa remain simplified 
with absence of alveolar branching. Alveolar lumens were markedly enlarged, compared 
to those of control animals, as a result of the decrease in alveolar septal complexity (Fig. 
13a).  An unequivocal and consistent difference in the cellularity or thickness of alveolar 
septa was not discernible. The alveolar size change was quantified by measuring the 
mean alveolar diameter (MAD), which is the mean of the longest distance between the 
walls of alveoli and by mean linear intercept (MLI) measurement which is a more 
extensive representation of alveolar septal development (Fig.13b). MAD measurements 
showed almost 50% increase in the longest diameter in BPD lung while MLI values for 
BPD was ~40 % more than the control lung (Fig. 13b).   
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Figure 13b - Mean alveolar diameter (MAD) and mean linear intercept measurements 
(MLI) of BPD and control rat pups 
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Figure 13a - H&E staining of BPD rat lung sections 
BPD was induced in new born rats by exposing them to ~95% oxygen from P3 to 
P13. The control pups from the same litter were kept side by side in atmospheric O2 
concentration for the same period. At the end of P13 the lung were isolated after 
proper fixation using 4% paraformaldehyde, sectioned and H&E stained.The upper 
panels represent the sections from control rat lungs (CON) and the lower panels 
contain sections from BPD lungs. a=alveolus, ta= terminal airway.  
13b - Mean alveolar diameter (MAD) and mean linear intercept measurements 
(MLI) of BPD and control rat pups 
H&E stained rat lung sections from BPD and control rats were taken and the mean 
diameter of individual alveoli was measured using MetaVue soft ware. MLI, 
representing the distance between inter-alveolar walls, which gives a more 
extensive measurement of alveolar sizes, was also measured in BPD and control rat 
lung sections. For MAD, at least 20 alveoli from 8 different fields were measured 
per lung section in relative units and expressed as %BPD. For MLI, at least 5 
different fields per section were analyzed and given in relative units as %BPD.  The 
data was from lung sections of 4 different rats per treatment. Value was expressed 
as mean ± SE. *** P< .005 vs Con. Paired t-test. 
Harts’s stain for elastin revealed significantly fewer secondary crests, which were 
distinctive because of their abundant elastic fibers (the black arrows), in BPD tissues than 
in control tissues (Fig. 2a). In most regions of the control lung, ~ 40 secondary crests 
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were recognized per single 20 X field.  In BPD lungs, secondary crests were less distinct 
because they contained fewer elastic fibers. Their presence was significantly less and 
their prevalence was regionally variable, averaging approximately 12 per 20X field.  The 
amount of elastic fibers in the alveolar septae of BPD lungs was subjectively less than 
that seen in alveolar septae of control lungs. Trichrome stains revealed an equivocal and 
subtle increase in collagen within the alveolar septa of BPD lungs when compared to 
control tissues (data not shown). There was no inflammatory infiltrates or signs of 
prominent fibrosis.  All these results demonstrated that the lesions in this model are 









Figure 14a - Evaluation of the formation of alveolar secondary crests 
Alveolar secondary crest formation was evaluated using the Harts’s elastin staining. 
Elastin which is abundant in the secondary crests can be visualized as purple stained 
areas in the sections (arrows). The upper and lower panel shows elastin staining in 
control (CON) and BPD lung, respectively.  
14b - Quantification of secondary crests 
The number of secondary crests per 20X filed were counted. At least 5 different fields 
per section were counted. The data was from lung sections of 4 different rats per 
treatment. Value was expressed as mean ± SE. *** = P < .005 v.s Con. Paired t-test.
Microarray and quantitative real time PCR verification of miRNAs differentially 
expressed in BPD 
To detect the miRNA expression profile in BPD, we used the miRNA microarray 
platform used in our laboratory (Wang et al., 2007). The microarray contained probes for 
227 non-redundant RNAs: 177 rat miRNAs, 5 human miRNAs, 31 mouse miRNAs and 
14 other kinds of RNAs and controls. miRNAs miR-342, miR-335, miR-150, miR-126* 
and miR-157* were significantly down regulated in the BPD lung while miR-21, miR-
141, miR-290 and miR-34a were upregulated. To further confirm this result, quantitative 
rtPCR was done and all the results were verified except for miR-290. The expression 
levels of downregulated (Fig. 15a) and the upregulated miRNA (Fig. 15b) in both 
microarray and qrtPCR, were given as a percentage to BPD.   
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Figure 15 - miRNA expression pattern in BPD  
Microarray and qrtPCR were done to determine the expression of various miRNAs 
that significantly changed in BPD lung. BPD and control rat lungs were collected, 
RNA isolated and used for microarray and qrtPCR. The results were expressed as 
percentage of BPD. 
a) Downregulated miRNAs in BPD 
miR-342, miR-335, miR-150, miR-126* and miR-151*.  
b) Upregulated miRNAs in BPD 
miR-21, miR-141 and miR-34a. The data was from samples of 4 different rat lungs 
per treatment. Value was expressed as mean ± SE. *** P value < 0.005 vs Con, ** 
P value < 0.01 vs Con and * P value < 0.05. Paired t-test. 
DISCUSSION 
In this study, we have identified miRNAs that were significantly changed in BPD using a 
microarray platform. Five miRNAs, namely, miR-342, miR-335, miR-150, miR-126* 
and miR-151* were down regulated in BPD. miRNAs miR-21, miR-141 and miR-34a 
and miR-290 were found to be up regulated in BPD. The results were further confirmed 
using qrtPCR. All miRNAs except miR-290 showed consistent expression trend when 
compared to microarray expression profile thus validating both our platform and data. 
We found Neonatal rats exposed to ~95% oxygen from P3 to P13 showed lesions 
consistent with that described for ‘new’ BPD. Decreased in number, large and simplified 
alveoli with fewer secondary alveolar crests have been the hall mark of new BPD with 
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other lesions like elastin formation, fibrosis, inflammation and airway epithelial 
proliferation varying from moderate to absent (Coalson, 2003; Bourbon et al., 2005). The 
new and milder form of BPD manifests in more immature infants and the primary cause 
for pathogenesis shifted from oxidative injury and mechanical ventilation to the 
immaturity of the developing lung that is forced to undergo gaseous exchange. The 
molecular mechanisms that contribute to both manifestation and progression of this 
disease are poorly understood. It has been shown that disruption of normal angiogenesis 
and improper development of capillaries in relation to the alveolar septa might be a major 
contributing factor towards manifestation of BPD (Jakkula et al., 2000; Kunig et al., 
2005). Abnormal  signaling mediated by vascular endothelial growth factor (VEGF), 
fibroblast growth factors (FGF) and insulin like growth factors (IGF) are thought to  
contribute to BPD (Veness-Meehan et al., 1997; Weinstein et al., 1998; Jakkula et al., 
2000; Kasahara et al., 2000; Afshar et al., 2003; Das & Ravi, 2004; Wagenaar et al., 
2004). All these pathways are major players in controlling proper lung development. 
Since impaired alveolar formation and subsequent defective development of the 
respiratory zone is an essential feature of BPD, understanding the molecular mechanisms 
that control proper septation and alveolarization can provide greater insights into 
pathogenesis of BPD. The advent of miRNA as one of the major regulatory components 
of biological process necessitates the study of its role in BPD pathogenesis. This, in turn, 
can bring new insights to the finer mechanisms of BPD pathogenesis. 
The role of miRNAs in controlling various biological processes ranging from organ 
development to virus invasion is subject of recent investigations.  Their importance in 
various developmental processes is established including embryonic cell differentiation, 
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embryo development, neuronal development, cardiac development, regulation of 
immunity and adipocyte differentiation and lung morphogenesis is established (Esau et 
al., 2004; Kanellopoulou et al., 2005; Lu et al., 2005; Harris et al., 2006; Hobert, 2006; 
Kloosterman & Plasterk, 2006; Rodriguez et al., 2007; van Rooij et al., 2007; Zhao et al., 
2007). Their role in modulating various forms of cancer and infectious diseases mediated 
by viruses have also been studied (Takamizawa et al., 2004; Eis et al., 2005; He et al., 
2005b; Yanaihara et al., 2006; Blenkiron & Miska, 2007; Triboulet et al., 2007). 
In the present study, the most interesting miRNAs that showed differential expression 
between BPD and control lung were miR-21 and miR-335. miR-21 was up regulated in 
BPD while miR-335 was down regulated. It is known that miR-335 is a potent metastasis 
suppressor, a proliferation inhibitor and an apoptosis promoter (Sathyan et al., 2007; 
Tavazoie et al., 2008). miR-21, on the other hand, is a potent proliferation promoter, 
tumor promoter and inhibitor of apoptosis (Chan et al., 2005; Meng et al., 2006; Si et al., 
2007; Zhu et al., 2007). It has been shown that knockdown of miR-21 can lead to the 
activation of caspases and cause increased cell death (Chan et al., 2005). More 
interestingly, it has also been demonstrated that miR-335 knockdown prevented cell 
death caused by miR-21 suppression and that miR-335 might be a functional antagonist 
of miR-21 (Sathyan et al., 2007). The opposite trends of expressions showed by these 
potentially antagonizing miRNAs in BPD might have some functional significance. 
Proper development of any organ involves controlled proliferation and apoptosis. Down 
regulation of miR-335 and concurrent up regulation of miR-21 is suggestive of a pro-
proliferative and anti-apoptotic signaling environment in BPD lung. There are ~ 170 
predicted targets for miR-335 and ~186 predicted targets for miR-21 as per the 
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TargetScan 4.2 algorithim (Lewis et al., 2003). But till date, only one target has been 
experimentally verified for miR-335 and two for miR-21. Sox-4, a transcription factor 
important in regulation of embryonic development and determination of cell fate is 
verified as a target for miR-335 (Kamachi et al., 2000; Tavazoie et al., 2008). The 
verified targets for miR-21 are tropomyocin and BCL-2, both tumor suppressor genes (Si 
et al., 2007; Zhu et al., 2007). These studies were performed in cancer cell lines. 
However since development involves controlled cell proliferation and cell death and a 
developmental disease like BPD might involve dysregulaton of these processes, the 
differential expression of these two miRNAs might have functional significance in BPD 
pathogenesis. 
Other predicted targets for miR-335 that might have functional significance in BPD 
includes dishevelled associated activator of morphogenesis 1(DAAM1), Smad nuclear 
interacting protein 1 (SNIP1), ubiquitin-conjugating enzyme E2H (UBC8), eukaryotic 
translation termination factor 1 (ETF), RAS p21 protein activator 1 (RASA1), mitogen-
activated protein kinase kinase kinase 2 (MAP3K2), insulin-like growth factor 2 mRNA 
binding protein 2 (IGF2BP2), fibroblast growth factor receptor substrate 2 (FRS2), 
homeobox B3 (HOXB3), integrin beta 8 (ITGB8) and  early growth response 3 (EGR3) 
(http://www.targetscan.org/cgi-bin/targetscan/vert_42/targetscan.cgi? 
species=Human&gid=&mir_c=&mir_sc=miR-335&mir_nc=&mirg=). miR-21 is 
predicted to target sprouty homolog 1 (SPRY1), fibroblast growth factor receptor 
substrate 2 (FRS2), Smad 7 and programmed cell death 4 (PDCD4) 
(http://www.targetscan.org/cgi-bin/vert_42/targetscan.cgi?mirg=rno-miR-21). It is 
interesting to note that all these targets are components of pathways that regulate 
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development by controlling proliferation, differentiation, cell migration or apoptosis. Of 
these targets, ITGB8, a target of miR-335 is known to play an important role in airway 
epithelial cell proliferation and cell matrix interactions by modulating transforming 
growth factor beta pathway (Fjellbirkeland et al., 2003). In tumor systems, It is also 
known to play an important role in mediating epithelial-mesenchymal transformations in 
unison with EGFR signaling pathways (Yan & Shao, 2006). So down regulation of miR-
335 in BPD might lead to dysregulation of these processes contributing to pathogenesis. 
For miR-21, the predicted target SPRY1 might be of great significance as it is an 
antagonizer of FGF signaling and also modulate EGF signaling (Hacohen et al., 1998; 
Egan et al., 2002). Both these signaling pathways are important in lung development.   
miR-342 is another miRNA that is down regulated in BPD. Just like miR-335, it is also 
shown to be pro-apoptotic tumor suppressor whose down regulation induces progression 
of colorectal cancer (Grady et al., 2008). miR-342 is located in the introns of the host 
gene EVL, a member of Ena/Vasp protein family important in controlling cytoskeleton 
remodeling, cell polarity and cell migration which is coordinately down regulated with 
miR-342 (Grady et al., 2008). Recently it has been shown to be a member of a large 
cluster of imprinted miRNAs expressed only from the maternal chromosome. The the 
cluster is present in a locus that is traditionally known to have genes important in 
development regulation (Seitz et al., 2004).  Other important predicted targets for miR-
342 includes bone morphogenetic protein receptor, type II (BMPR2), nuclear respiratory 
factor 1(NRF1), homeobox B8 (HoxB8) and insulin-like growth factor 2 mRNA binding 
protein 3 (IGF2BP3). BMPR2 is known to have important role in modulating 
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morphogenesis while NRF1 is a transcription factor that regulates some key metabolic 
genes important in cell growth and regulation of respiration. 
miR-126* is also down regulated in BPD and it has been known that  miR-126* is 
located on a region that is deleted in lung cancer (Yanaihara et al., 2006). The gene for 
miR-126* was down regulated in almost all types of lung cancer. miR-126*, therefore, 
might have an anti-proliferative. 
miR-150, another down regulated miRNA in BPD,  have predicted targets like vascular 
endothelial zinc finger 1 (VEZF1) implicated in vascular development. Since improper 
development of vasculature is a contributing factor to BPD, this might be of functional 
significance. Other important targets for miR-150 include insulin-like growth factor and 
mitogen-activated protein kinase kinase kinase 12, which contribute to multiple signaling 
processes important in development. miR-151*, which is also down-regulated in BPD, 
has the predicated targets insulin-like 3 precursor and LIM homeobox 9. these genes are 
important in development of multiple organs (Hunter & Rhodes, 2005). 
It is both interesting and contrasting to note that one of the upregulated miRNAs in BPD, 
miR-34a, is a tumor suppresser. It is anti-proliferative, pro-apoptotic and can induce cell 
cycle arrest by down regulating CCND1 and CDK6 (Chang et al., 2007; Tazawa et al., 
2007). miR-141, another up regulated miRNA, is a member of miRNA-200 family which 
have 5 members. Their down regulation is shown to be essential for epithelial-
mesenchymal transitions, which are important in organ development and early tumor 
metastasis (Gregory et al., 2008). The upregulation of this family can inhibit epithelial-
mesenchymal transition by targeting transcriptional repressors of E-cadherin namely 
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ZEB1 and ZEB2 (Gregory et al., 2008; Korpal et al., 2008).  Since miR-141 expression is 
significantly up regulated in BPD, this might have some effect on the differentiation 
process involved in lung development too and might contribute to the pathogenesis. 
As we see the functional implications of the targets of both up regulated and down 
regulated miRNAs in BPD, there is no clear cut demarcation that one set have targets that 
down regulates one process while the other have targets that exclusively antagonizes the 
same process. Both up regulated and down regulated miRNAs have potential targets that 
can modulate a variety of processes. The regulatory mechanisms involving miRNAs 
seems to be much more complex and can fill the whole spectrum ranging from functional 
antagonism to a significant degree of agonism. However, the present study has given us 
insights into the miRNAs that might be important players in modulating BPD 
pathogenesis. To decipher, the role of each individual miRNA in relation to others is the 
subject of our current investigations. 
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CHAPTER V 
HEMOGLOBIN IS EXPRESSED IN ALVEOLAR EPITHELIAL TYPE II CELLS 
ABSTRACT 
Hemoglobin is the main oxygen carrying heme protein in erythrocytes. In an effort to 
study the differential gene expression of alveolar epithelial type I and type II cells using 
DNA microarray technique, we found that the mRNAs of hemoglobin α- and β-chains 
were expressed in type II cells, but not in type I cells. The microarray data were 
confirmed by RT-PCR. The mRNA expression of both chains decreased when type II 
cells trans-differentiated into type I-like cells. Immunocyto/histochemistry revealed that 
hemoglobin protein was specifically localized in type II cells of a lung cell mixture and 
rat lung tissue.  The endogenous synthesis of hemoglobin in alveolar epithelial cells 
suggest that hemoglobin may have unidentified functions other than oxygen transport in 
the lung. 
Key words: Hemoglobin, Trans-differentiation, Alveolar Epithelial Cells. 
INTRODUCTION 
Alveolar epithelium of the lung is primarily composed of two kinds of cells: type I cells 
(AEC I) and type II cells (AEC II). The AEC I are large squamous cells while AEC  II  
are cuboidal in shape (Crandall and Matthay, 2001). Even though the number of AEC II 
is roughly twice as much as type I cells, AEC II occupy only a small percentage of 
alveolar surface area (<5%) and are mainly limited to the corners of alveoli. These cells 
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are also functionally different.  AEC I are the main epithelial component of the thin air–
blood barrier. AEC II have important secretory capacities, such as the secretion of the 
lung surfactant, and are the progenitor cells for the terminally differentiated AEC I 
(Fehrenbach, 2001; Warburton and Bellusci, 2004). Because of the difference in the 
functions of these two cell types, there are a large number of genes and proteins 
differentially expressed in these cells and many of them have been used as markers for 
the specific cell type (Dobbs et al., 1985; Kalina et al., 1992; Padro et al., 1990).   
Hemoglobin is one of the most abundant heme-binding proteins and consists of two α- 
and two β-globin polypeptides, which form a heterotetramer with a heme moiety in each 
monomer.  The primary function of hemoglobin has been attributed to oxygen binding 
and transport in the blood circulation.  Other heme binding proteins like cytochromes, 
extracellular peroxidases, and cytoglobin, neuroglobin, and myoglobin have roles in 
catalysis, oxygen consumption, cytoprotection and oxygen sensing (Brunori, 2001; 
Burmester and Hankeln, 2004; Edgar and Polak, 2001; Hardison, 1998). In this paper, we 
report, for the first time, the expression of hemoglobin in AEC II of the lung. This finding 
is novel in the way that no other known cell population, other than erythrocytes and their 
progenitors, was reported to express this protein under normal physiological conditions.  
Further functional studies in this direction may uncover unidentified roles of hemoglobin 
in the alveolar epithelium.  
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MATERIALS AND METHODS 
Isolation and culture of AEC II  
AEC II were isolated from pathogen free male Sprague-Dawley rats (250-275g) by the 
improved method as previously described by us (Chen et al., 2004). In brief, the perfused 
lungs were lavaged and digested with elastase (3 units/ml, Worthington Biochemical 
Corporation, Lakewood, NJ). The cell mixture was filtered through 160- and 37-µm 
nylon mesh once, and 15-µm nylon mesh twice, and plated on rat IgG-coated plates to 
remove macrophages. The unattached cells from IgG plates were further incubated with 
anti-Leukocyte Common Antigen (anti-LC, 40 µg/ml) (Accurate, Westbury, NY), rat IgG 
(70 µg/ml), and anti-T1 α antibodies for 30 minutes at 40C. The cells were then 
incubated for 20 min with anti-rat and anti-mouse IgG-conjugated magnetic beads (Dynal 
Biotech, Lake success, NY). A magnetic field was applied to remove the cells attached to 
the magnetic beads. The purity of AEC II was >96 as determined by modified 
Papanicolaou staining and the viability was >98% Freshly isolated cells were directly 
used for DNA microarray analysis and RT-PCR. AEC II were also seeded onto 35 mm 
tissue culture-treated plastic dishes at a density of 1.3 x 106 cells per dishes in Minimum 
Essential Medium (MEM) with 10 % fetal bovine serum and cultured for 1 to 7 days. In 
this culture system, the trans-differentiation of AEC II to AEC I-like cells becomes 
evident from day 3 onward and was nearly complete by day 5.  
Isolation of AEC I  
AEC I was isolated according to our recently published protocol (Chen et al., 2004). The 
perfused lungs were digested three times with 4.5 U/ ml elastase at 37°C for 10 minutes. 
After being filtered through 160- and 37-µm nylon mesh, the resulting cell mixture was 
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panned on a rat IgG-coated bacteriological Petri dish for 30 min at 37°C. The cells were 
then incubated with rat IgG (40 µg/ml) and anti-LC (40 µg/ml), followed by the 
incubation with sheep anti-rat IgG Dynabeads (100 µl/rat) and goat anti-mouse IgG 
Dynabeads (100 µl/rat) at 4°C for 20 min. The beads were removed and the cells were 
further incubated with rabbit anti-rat T1α antibodies (40 µg/ml) at 4°C for 40 min. AEC I 
were collected by the incubation with goat anti-rabbit IgG BioMag beads. The purity of 
AEC I was >90% and the viability was >95%. 
Isolation of lung cell mixture  
The procedure was the same as for the isolation of AEC I.  The cell mixture was collected 
after filtering and cytospinned onto microscopic glass slides. The cells were fixed with 
4% paraformaldehyde and used for immunocytochemistry.  
Microarray analysis  
The total RNAs from isolated AEC II and AEC I were extracted using TRI reagents 
(Molecular Research Center, Cincinnati, OH) and used for cDNA synthesis and 2-step 
microarray hybridization with 3DNA 50 Expression kit (Genisphere Inc., Hatfield, PA). 
Total RNA was reverse-transcribed with Cy3- or Alexa 647-specific primers. The cDNA, 
thus obtained, was purified with the Microcom YM-30 columns (Millipore, Billerica, 
MA) and mixed with 2x formamide hybridization buffer (50% formamide, 6x SSC, 0.2% 
SDS) for hybridization at 42ºC for 48 hours. The slides were washed and incubated with 
Cy3- and Alexa 647-specific capture reagents at 42ºC for 2 hours. The slide was scanned 
by a laser confocal scanner, ScanArray Express (PerkinElmer Life and Analytical 
Sciences, Boston, MA). Hybridization images were analyzed using GenePix pro 4 
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software (Axon Instruments, Inc. Union City, CA). Data analysis were performed using 
our in-house software Realspot (Chen and Liu, 2005) and SAM package. The details of 
microarray experiments and the whole data set will be published elsewhere . 
Reverse Transcription- Polymerase Chain Reaction 
 PCR primers were as follows:  
β chain of hemoglobin,  
Forward, 5’-TGTGACAAGCTGCATGTGGAT-3’, 
Reverse, 5’-TGACCATTGCACAAAGACAAGA-3’,  
α-chain of hemoglobin,  
Forward, 5’- CCACTCTGAGCGACCTGCAT-3’,  
Reverse, 5’- GGTGCTCAC AGAGGCAAGGA-3’,  
18S RNA, 
Forward, 5’- TCCCAGTAAGTGCGGGTCATA-3’,  
Reverse, 5’-CGAGGGCCTCACTAAACCATC-3’.  
One microgram of total RNA was reverse-transcribed into cDNA using Super script II 
(Invitrogen, Carlsbad, CA). The PCR was performed using the following conditions: 96º 
for 5 minutes, followed by denaturation at 94ºfor 30 seconds, annealing at 60º for 30 
seconds, and extension at 72 º for 30 seconds. The PCR product was then visualized by 
agrose gel electrophoresis. 
Immunocytochemistry and Immunohistochemistry  
 Paraffin embedded tissue sections of perfused rat lung were dewaxed using xylene, 
rehydrated using descending grades of ethanol, and washed in phosphate buffer saline 
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(pH 7.4). Antigen retrieval was done by boiling the slides for 15 minutes in 20 mM 
citrate buffer (pH 6.0). The subsequent steps were the same for both 
immunocytochemistry and immunohistochemistry. Briefly, the fixed tissues or 
cytospinned cells were permeabilized with 0.4% Triton X-100 for 20 minutes and 
blocked for one hour in 10% fetal bovine serum .The slides were then incubated with 
mouse anti-LB-180 (1:200 dilution) (Covance, Richmond, CA) and rabbit anti-rat 
hemoglobin (1:300 dilution) (Biogenesis, Poole, England) antibodies for overnight at 
40C. The slides were then washed and incubated with Alexa 568-conjugated anti-rabbit 
and Alexa 488-conjugated anti-mouse secondary antibodies (Jackson Immuno Res, PA). 
Slides were then washed and mounted on an antifade medium (5% n-propyl gallate and 
80% glycerol in PBS) and viewed through a Nikon Eclipse E600 fluorescence 
microscope. 
RESULTS  
Hemoglobin was highly expressed in AEC II and not in AEC I 
Using our in-house 10K rat gene DNA microarray, we performed gene profiling of 
freshly isolated AEC I and AEC II. Two of the genes with the highest fold change 
between AEC II and AEC I were α-chain (NM_013096) and ß-chain (NM_033234) of 
hemoglobin. The ratios between AEC II and AEC I were 13.8 ± 1.2 and 7.4 ± 1.2, 
respectively (means ± SE, n=30) (Fig. 1A). Two other hemoglobin probes (X56327 and 
M32509) in the 10K set also showed a similar change (9.3 ± 1.2 and 9.1 ± 1.2). The 
M32509 probe corresponds to the ß -chain mRNA  3’ end and has a sequence similarity 
of 96 % to the 3’ end of NM_033234. The X56327 probe represents epsilon 2 globin 
gene. Three related heme proteins, cytoglobin (Burmester et al., 2002a; Pesce et al., 
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2002a), neuroglobin (Burmester and Hankeln, 2004c; Pesce et al., 2002b), and myoglobin 
(Brunori, 2001b) were not expressed in both cell types in our microarray data set. RT-
PCR analysis showed that the mRNAs of hemoglobin α- and ß-chains were highly 
expressed in AEC II, but was not detectable in AEC I (Fig. 16B), validating the 




Figure 16 - The mRNA expression of hemoglobin in alveolar epithelial cells.  
(A) DNA microarray.  The ratios of AEC II and AEC I were from 10K rat gene DNA 
microarray hybridizations and are presented as means ± SE (n=30, 5 biological and 6 
technical replications). Two probes from the β chains of hemoglobin (NM_033234, and 
M32509), one from epsilon 2 (X56327), and one from α chain (NM_013096) were shown. 
(B) RT-PCR. The total RNA from 3 independent AEC II and AEC I preparations were 
reversed transcribed to cDNA. The α- and β-chain of hemoglobin PCR-amplified for 30 
cycles. 18S rRNA was used as a control.  
The mRNA expression of hemoglobin decreased as AEC II trans-differentiate to 
AEC I-like cells 
Although the purity of AEC II was >96%, the possibility still exists regarding 
contaminations in our cell preparations. We further examined the mRNA expression of 
hemoglobin during the trans-differentiation of AEC II to AEC I-like cells. When being 
cultured on tissue culture treated plastic dishes, AEC II gradually converted to AEC I-like 
cells. The latter had a similar cell shape as AEC I and express AEC I markers, but lacked 
AEC II markers.  By day 2, the trans-differentiation began and was completed by day 5 to 
day 7, depending on culture conditions. The cells were collected on Day 0, 1, 3, and 5 
and total RNA extracted. RT-PCR analysis revealed that both chains of hemoglobin were 
expressed on day 0 and gradually decreased as the trans-differentiation initiated (Fig. 17).  
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Figure 17 - The mRNA expression of hemoglobin during the trans-differentiation of AEC 




Figure 17 - The mRNA expression of hemoglobin during the trans-differentiation 
of AEC II into AEC I-like cells 
 Freshly isolated AEC II were seeded on plastic dishes in MEM medium containing 
10 % FBS and cultured for 0 (D0), 1 day (D1), 3 days (D3) , 5 days (D5), and 7 
days (D7). Total mRNAs was extracted from cultured cells and RT-PCR was 
performed to detect α-, and β-chains of hemoglobin. 18S rRNA was used as a 
control. Panel A, representative gels; and panel B, quantitation. The results were 
expressed as a percentage of control (D0). Data shown are means ± SE. *P<0.05 
(n=3 independent cell preparations) Black bar: α-chain; dotted bar: β-chain
Hemoglobin is specially expressed in AEC II of a lung mixture cell population  
To further examine the expression of hemoglobin at the protein level in AEC II, we 
isolated a population of mixed cells from the rat lung as described in the Materials and 
Methods, and cytospinned onto microscopic glass slides. This mixture of cells consisted 
of AEC I, AEC II, Clara cells, ciliated airway epithelial cells, fibroblasts, macrophages, 
and lymphocytes. LB-180, an AEC II marker, was used to identify AEC II in the mixture. 
The double labeling with anti-hemoglobin and anti-LB-180 antibodies revealed the co-
localization of hemoglobin with LB-180 in AEC II, but not in other cells (Fig. 18a-d). 
The omission of primary antibodies did not generate any signals (Fig. 18e-h).  
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Figure 18 - Double-labeling of a lung cell mixture for LB-180 (an AEC II marker) 
and hemoglobin 
A lung cell mixture was cytospinned onto microscopic glass slides. The slides were 
incubated with rabbit anti-hemoglobin and mouse anti-LB-180 antibodies, followed 
by incubation with Alexa 568-conjugated anti-mouse and Alexa 488-conjugated 
anti-rabbit IgG (Panels a-d). The negative control without primary antibodies was 
shown in Panels e-h. Scale bar: 5 μm. 
Hemoglobin is localized in AEC II of the lung  
The gene and protein expression could be potentially affected by cell isolation 
procedures. To avoid this problem, we directly immunostained rat lung tissue. The rat 
lung was perfused to remove red blood cells before fixation and sectioning. Once again, 
LB-180 was used as an AEC II marker. The results revealed that hemoglobin was 
localized in the corners of the alveoli, which were occupied by AEC II. The hemoglobin 
staining pattern was the same as LB-180 (Fig. 19 a-h). The control without primary 
antibodies did not have signals (Fig. 19i-l). The result indicated that hemoglobin protein 
was localized only in AEC II, but not in AEC I and other lung cell types in the normal rat 
lung. The endothelial cells did not show any staining for hemoglobin while the airway 
epithelium showed faint positive staining (data not shown).  
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Figure  19 - Double-labeling of rat lung tissue sections for LB-180 (AEC II marker) 
and hemoglobin.  
Rat lung tissue sections were incubated with rabbit anti-rat hemoglobin and mouse 
anti-LB -180 antibodies, followed by incubation with Alexa 568-conjugated anti-
mouse or Alexa 488-conjugated anti-rabbit IgG (Panels a-h).  The negative control 
was without primary antibodies (Panels i-l).  
Scale bars: 20 μm for x40 and 8 μm for 100x 
DISCUSSION 
Aside from its most important and well-known function, oxygen transport, hemoglobin 
also has a variety of other functions. These functions include being a molecular heat 
transducer by virtue of its oxygenation-deoxygenation cycle, the alteration of red blood 
cell metabolism, hemoglobin oxidation, enzymatic activities, and drug interactions 
(Hardison, 1998). Since oxygen can be a damaging agent to the cells exposed to it, the 
oxygen binding hemoglobins may have a role in the protection of cells from the damage 
(Hardison, 1998). Hemoglobin is also thought to be involved in the protection of cells 
against nitrosative stress (Gardner et al., 1998; Hausladen et al., 1998). Recent studies 
have shown that hemoglobin can bind and release NO as a redox reaction, thus 
functioning in close resemblance to cytochromes (Gow and Stamler, 1998). Neuroglobin 
and cytoglobin, two other members of the vertebrate globin family, also have protective 
functions including oxygen sensing and scavenging (Burmester et al., 2002; Burmester 
and Hankeln, 2004; Pesce et al., 2002). Neuroglobin is predominantly expressed in the 
nervous system while cytoglobin is present in almost all tissues. Even though their amino 
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acid and gene sequences are distinct from each other, their functional structure has 
striking similarities. The related globins in fungi and bacteria are involved in electron 
transport and protection from oxidative stress (Hardison, 1998).   
A long standing notion that hemoglobin gene can only be expressed in the cells of 
erythroid lineage has been challenged by a recent study, in which the treatment with 
lipopolysaccharide and interferon-  led to the activation of the β globin gene in murine 
macrophages (Liu et al., 1999). In the current study, we provide evidence that 
hemoglobin was specially expressed in AEC II of the lung. Since AEC II are in close 
proximity to environmental air, blood circulation, and facing the conditions of altered 
gaseous environment around it, our finding may have an important functional 
significance. We speculated the following possible functions of hemoglobin in the lung: 
(i) facilitate oxygen transport across the air-blood barrier; (ii) behave as an oxygen 
sensor; and (iii) function as oxygen or nitric oxide scavenger and thus protect alveolar 
epithelium from oxidative/nitrosative stress. Further studies are needed to uncover un-
identified functions of hemoglobin in the lung.  
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CHAPTER VI 
SUMMARY AND CONCLUSION 
The first aim of the present study was to understand the role of TGF β1 and its down 
stream signaling components in alveolar epithelial trans-differentiation, a phenomenon 
seen in acute lung injuries. The second aim was to determine the expression profile and 
possible roles of microRNAs in fetal lung development and in a chronic lung disease of 
development called Bronchopulmonary dysplasia (BPD). 
The expression of TGF β1 and the components of its signaling pathway was studied in an 
in vitro trans-differention model. Trans-differentiation was monitored by using cell type 
specific markers, LB-180 for AEC II and P2X7 for AEC I.  We for the first time 
demonstrated that the in vitro trans-differentiation model was bi-phasic with an initial 
proliferation phase and a later differentiation phase. Even though TGF β1 and Smad 4 
were highly expressed in normal AEC II cells, isolation and culturing initially reduced 
the  expression of TGF β1. The initial proliferation phase had low expression of TGF β1 
and its down stream effectors Smad 2 and Smad 3 including their phosphorylated forms. 
The expression of anti-proliferative p15Ink4b and p21 kip1 were also downregulated during 
the proliferative phase with a concurrent upregulation of pro-proliferative CDKs 2, 4 and 
6. This expression profile was completely reversed during the differentiation phase. 
There was increased secretion of TGF β1 into the media during the differentiation phase 
indicating that the active signaling is autocrine in nature. We demonstrated that the 
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concurrent increase of both phosphorylated and unphosphorylated Smads 2 &3, p15 Ink4b 
and p21kip1 and decrease of CDKs 2, 4 and 6 were facilitated the transition from 
proliferation phase to differentiation phase. The addition of TGF β1 in the pre-
proliferative phase blocked the trans-differentiation process. Moreover the addition of 
TGF β1after the proliferation phase did not have any effect. This demonstrated that the 
initial proliferation phase was necessary for the differentiation to take place. This view 
was further strengthened by the fact that blocking of TGF β1 by the antibody completely 
stopped the trans-differentiation process. To prove that TGF β1 is essential for trans-
differentiation and the signaling is Smad-dependent, we knocked down the expression of 
common partner Smad 4 which is essential for Smad-mediated TGF β1 signaling. 
Silencing of Smad 4 resulted in blocking of trans-differentiation process. These results 
demonstrated that the trans-differentiation of AEC II to AEC I was mediated by 
autrocrine signaling through Smad-mediated TGF β1 pathway. The effect was elicited by 
altering the expression of proteins that controlled G1 to S phase entry in cell cycle. 
Since miRNAs are important regulators of development and disease, the later part of this 
study has focused on the profiling of miRNAs during lung development and in a chronic 
lung disease named BPD.  A miRNA microarray platform was used to profile miRNAs 
that are differentially expressed during fetal lung development. 21 microRNAs that 
showed significant changes during fetal lung development and were grouped into 4 
distinct clusters based on their expression pattern. Using rtPCR, the expression pattern of 
6 miRNAs that were representative of these clusters were verified.  In situ hybridization 
demonstrated that miR-127 expression gradually shifted from mesenchymal cells to 
epithelial cells as development progressed. miR-127 was chosen for further functional 
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studies. Using an in vitro lung culture system, we overexpressed miR-127 in the 
developing lung. This significantly decreased the terminal bud count, increased terminal 
and internal bud sizes and caused unevenness in bud sizes, indicating improper 
development. These findings suggest that miR-127 may have an important role in fetal 
lung development. 
For the BPD studies, we first established a rat model of the disease where the pathology 
corresponded to that described for ‘new’ BPD. Using the samples from this model 
miRNA microarray was done to see the miRNAs that showed significant change in BPD. 
miR-342, miR-335, miR-150, miR-126* and miR-151* were  down regulated  and miR-
21, miR-141, miR-290 and miR-34a were up regulated in BPD. The expression profiles 
of eight of these miRNAs were confirmed using quantitative real-time PCR and their 
possible functional significance have been discussed. 
In an effort to study the differential gene expression of alveolar epithelial type I and type 
II cells using DNA microarray technique, we found that hemoglobin was present in AEC 
II and not in AECI. Hemogobin is the main oxygen carrying component of erythrocytes. 
The presence of both α- and β-chains of hemoglobin was confirmed in type II cells, but 
not in type I cells. Their expression decreased as AEC II trans-differentiated to AECI. 
The protein form was also found to be specifically localized in AEC II both in adult lung 
and in a mixed cell population. This is the first study to our knowledge that has identified 
hemoglobin in a cell type other than erythrocytes. This study also points to the possibility 
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The present study was undertaken to understand the role of TGF β1 and its down-stream 
signaling components in alveolar epithelial trans-differentiation, a phenomenon seen in 
acute lung injuries. The second aim was to elucidate the expression profile and possible 
roles of microRNAs in fetal lung development and in a chronic lung disease of 
development called Bronchopulmonary dysplasia (BPD). An in vitro model for trans-
differentiation of alveolar epithelial cells was used and expression of TGF β1 and 
multiple components of its pathway and the effect of blocking the pathway on the process 
were looked into. The microRNA expression profile during different time points in fetal 
lung development was characterized and confirmed. Effect of miR-127 over expression 
on lung branching and morphology in an in vitro organ culture system was visualized and 
quantified using morphometric analysis. The BPD model in neonatal rat was established 
and microRNAs that significantly changed during disease and their expression pattern 
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Findings and Conclusions:   
1. The trans-differentiation of alveolar epithelial type 2 cells to type 1 was modulated by 
autocrine signaling through TGF β1 pathway and was Smad mediated. 
2. TGF β1 elicited its effect by altering the expression levels of cell cycle proteins, 
CDKs2, 4 and 6 and p15Ink4b and p21kip1. 
3. Blocking the signaling through TGF β1 blocked the trans-differentiation process. 
4. 21 microRNAs were identified that showed significant changes during fetal lung 
development and grouped into 4 distinct clusters based on their expression pattern. 
5. miR-127 over expression significantly affected lung branching and morphogenesis  
implicating its role in fetal lung development. 
6. A neonatal rat model for BPD was established. 
7. 5 down-regulated and 4 up-regulated microRNAs were identified in BPD, providing 
an insight into the pathogenesis of BPD. 
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